[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 424
1. Cao D, Ji H, Ronnett BM: Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary. Int J Gynecol Pathol; 2005 Jan;24(1):67-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary.
  • Metastatic pancreatic mucinous adenocarcinomas in the ovaries can be difficult to distinguish from primary ovarian mucinous neoplasms because the former can simulate the latter grossly and histologically and both tumor types share the same cytokeratin 7/cytokeratin 20 immunoprofile.
  • We previously reported the utility of loss of Dpc4 expression in distinguishing metastatic pancreatic carcinomas from primary ovarian mucinous tumors.
  • In this study we investigate the expression patterns of these markers in 35 primary ovarian mucinous tumors (28 atypical proliferative [borderline] tumors and 7 invasive carcinomas) and 11 metastatic pancreatic mucinous carcinomas in the ovary.
  • Primary ovarian mucinous tumors expressed mesothelin (17%), fascin (26%), and PSCA (43%) less frequently than metastatic pancreatic adenocarcinomas (73%, 73%, and 82%, respectively).
  • Expression of all three markers was seen only in metastatic pancreatic adenocarcinomas (45%), and coexpression of at least two markers was observed significantly more frequently in metastatic (82%) than primary ovarian mucinous tumors (17%).
  • Our results indicate that an immunohistochemical panel including Dpc4, mesothelin, fascin, and PSCA is useful for evaluating difficult mucinous tumors in the ovary when the differential diagnosis includes metastatic pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Biomarkers, Tumor / metabolism. Carrier Proteins / metabolism. Membrane Glycoproteins / metabolism. Microfilament Proteins / metabolism. Neoplasm Proteins / metabolism. Ovarian Neoplasms / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Antigens, Neoplasm. Diagnosis, Differential. Female. GPI-Linked Proteins. Humans. Immunohistochemistry. Probability

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15626919.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / Microfilament Proteins; 0 / Neoplasm Proteins; 0 / PSCA protein, human; 0 / mesothelin; 146808-54-0 / fascin
  •  go-up   go-down


2. Benit A, Allard J, Rimailho J, Fauvel J, Escourrou G, Vezzosi D, Donadille F, Bennet A, Caron P: Persistent and moderate hypercalcemia related to an ovarian clear cell adenocarcinoma: Pre- and postoperative parathyroid hormone related-peptide and 1,25-dihydroxyvitamin D3 levels. J Endocrinol Invest; 2006 May;29(5):443-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistent and moderate hypercalcemia related to an ovarian clear cell adenocarcinoma: Pre- and postoperative parathyroid hormone related-peptide and 1,25-dihydroxyvitamin D3 levels.
  • OBJECTIVE: To evaluate the role of PTH-related peptide (PTH-rP) and 1,25-dihyhydroxyvitamin D3 in a case of hypercalcemia related to an ovarian adenocarcinoma.
  • DESIGN: We report a case of humoral hypercalcemia in a patient aged 74 yr with a clear cell adenocarcinoma of the right ovary at an early stage of its development (stage T1aN0M0) revealed by moderate and persistent hypercalcemia (variable level between 2.7 and 3.2 mmol/l without any treatment) over six months.
  • METHODS: PTH-rP and 1,25-dihydroxyvitamin D3 were measured in blood samples taken before and after hysterectomy and bilateral salpingooophorectomy and in blood samples taken intraoperatively from the right ovarian vein and a peripheral vein.
  • A concentration gradient was found regarding plasma PTHrP (right ovarian vein 60.4 pmol/l, peripheral vein 4.5 pmol/l), not 1,25-dihydroxyvitamin D3.
  • CONCLUSION:. 1) moderate and persistent hypercalcemia can be observed at an early stage of an ovarian carcinoma;.
  • 2) the gradient of PTH-rP concentration between the samples taken from the right ovarian vein and a peripheral vein provides evidence for a direct secretion of PTH-rP by the ovarian tumor;.
  • 3) the increased 1,25-dihydroxyvitamin D3 level is not related to a direct ovarian production, but is a consequence of PTH-rP secretion.
  • [MeSH-major] Adenocarcinoma, Clear Cell / complications. Calcitriol / blood. Hypercalcemia / etiology. Ovarian Neoplasms / complications. Parathyroid Hormone-Related Protein / blood

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1980 Dec 11;303(24):1377-83 [6253785.001]
  • [Cites] J Endocrinol. 2001 Nov;171(2):249-57 [11691644.001]
  • [Cites] Am J Pathol. 2004 Sep;165(3):807-13 [15331405.001]
  • [Cites] Gynecol Oncol. 2000 Feb;76(2):218-22 [10637074.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Jun;70(6):1559-63 [2347892.001]
  • [Cites] Biol Reprod. 2000 Feb;62(2):334-9 [10642570.001]
  • [Cites] Endocrinology. 1989 May;124(5):2057-62 [2539966.001]
  • [Cites] Int J Gynecol Pathol. 2004 Oct;23(4):330-6 [15381902.001]
  • [Cites] Cancer. 1991 Aug 1;68(3):642-7 [2065286.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Nov;71(5):1112-8 [2229275.001]
  • [Cites] J Clin Invest. 1985 Aug;76(2):695-702 [3928683.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Apr;88(4):1603-9 [12679445.001]
  • [Cites] Blood. 1989 Jan;73(1):235-9 [2910361.001]
  • [Cites] J Clin Endocrinol Metab. 1994 May;78(5):1268-70 [8175989.001]
  • [Cites] Hum Pathol. 1997 Mar;28(3):379-82 [9042805.001]
  • [Cites] Int J Gynecol Pathol. 2004 Oct;23(4):393-7 [15381910.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Jun;74(6):1468-70 [1592895.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Sep;79(3):912-5 [8077382.001]
  • [Cites] Endocrinology. 1986 Jul;119(1):303-10 [3013591.001]
  • [Cites] N Engl J Med. 1990 Apr 19;322(16):1157 [2320085.001]
  • [Cites] Obstet Gynecol Surv. 1980 Mar;35(3):129-36 [6987579.001]
  • [Cites] Science. 1987 Dec 11;238(4833):1566-8 [3685994.001]
  • [Cites] Gynecol Oncol. 2004 Apr;93(1):269-71 [15047251.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1999 Feb;82(2):227-9 [10206422.001]
  • [Cites] Ann Intern Med. 1985 Jun;102(6):776-9 [3994189.001]
  • [Cites] N Engl J Med. 1990 Nov 8;323(19):1324-8 [2215618.001]
  • [Cites] Annu Rev Med. 1994;45:189-200 [8198376.001]
  • [Cites] J Bone Miner Res. 1994 Apr;9(4):521-6 [8030440.001]
  • [Cites] Cancer. 1971 Feb;27(2):427-33 [5100404.001]
  • [Cites] J Clin Endocrinol Metab. 1989 May;68(5):976-81 [2541161.001]
  • [Cites] Endocrinol Metab Clin North Am. 2000 Sep;29(3):629-45 [11033764.001]
  • [Cites] Lancet. 1991 Jan 19;337(8734):140-1 [1670789.001]
  • [Cites] Ann Intern Med. 1990 Apr 1;112(7):499-504 [2138442.001]
  • [Cites] Am J Clin Pathol. 1996 Apr;105(4):487-92 [8604692.001]
  • [Cites] Am J Hematol. 1993 Jul;43(3):240-2 [8352245.001]
  • [Cites] Ann Intern Med. 1994 Nov 1;121(9):633-40 [7944070.001]
  • [Cites] Cancer. 1994 Apr 15;73(8):2223-30 [8156530.001]
  • [Cites] J Clin Endocrinol Metab. 1993 May;76(5):1373-5 [7684395.001]
  • [Cites] Endocrinology. 1989 May;124(5):2172-8 [2539970.001]
  • [Cites] Mol Cell Endocrinol. 1997 Apr 25;129(1):91-9 [9175633.001]
  • [Cites] Gynecol Oncol. 2000 Dec;79(3):504-7 [11104629.001]
  • [Cites] Blood. 1993 Sep 1;82(5):1383-94 [8364192.001]
  • [Cites] Cancer. 1992 Dec 15;70(12):2845-50 [1451066.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1878-81 [8137214.001]
  • [Cites] Endocr Pract. 2003 Sep-Oct;9(5):389-93 [14583422.001]
  • (PMID = 16794368.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Parathyroid Hormone-Related Protein; FXC9231JVH / Calcitriol
  •  go-up   go-down


3. Ciocca V, Bombonati A, Palazzo JP, Schulz S, Waldman SA: Guanylyl cyclase C is a specific marker for differentiating primary and metastatic ovarian mucinous neoplasms. Histopathology; 2009 Aug;55(2):182-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guanylyl cyclase C is a specific marker for differentiating primary and metastatic ovarian mucinous neoplasms.
  • AIMS: The aim was to assess the value of GCC in distinguishing primary ovarian mucinous neoplasms from metastatic mucinous adenocarcinomas with ovarian involvement.
  • METHODS AND RESULTS: Fifty ovarian tumours: 27 primary ovarian mucinous neoplasms (seven cystadenomas, 10 borderline tumours and 10 cystadenocarcinomas) and 23 metastatic mucinous adenocarcinomas with ovarian involvement [13 colorectal adenocarcinomas, four gastric adenocarcinomas, six appendiceal mucinous tumours (four adenocarcinomas, one with neuroendocrine features, and two appendiceal mucinous cystadenomas)] were studied.
  • For primary ovarian mucinous neoplasms, 25 of 27 were negative for GCC.
  • Twelve of 13 cases of colorectal adenocarcinoma (except for one neuroendocrine adenocarcinoma) were positive for GCC.
  • Three of four appendiceal mucinous adenocarcinomas were positive for GCC in both the primary and metastatic tumours (except for one neuroendocrine adenocarcinoma).
  • Of four cases of gastric adenocarcinoma with ovarian involvement, only one (primary tumour) exhibited focal GCC staining.
  • CONCLUSIONS: GCC is a useful marker for differentiating between primary and secondary ovarian mucinous neoplasms.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2000 Jul;119(1):89-96 [10889158.001]
  • [Cites] Mod Pathol. 2006 Nov;19(11):1421-8 [16980943.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5151-7 [11016642.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7846-51 [11438734.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):281-92 [12604884.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2695-9 [12594332.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):985-93 [12826891.001]
  • [Cites] Virchows Arch. 2003 Dec;443(6):782-6 [14576939.001]
  • [Cites] Am J Physiol. 1983 Oct;245(4):G492-8 [6312810.001]
  • [Cites] Cell. 1990 Nov 30;63(5):941-8 [1701694.001]
  • [Cites] J Biol Chem. 1991 Sep 25;266(27):17912-8 [1680854.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Feb 1;89(3):947-51 [1346555.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10464-8 [7902563.001]
  • [Cites] J Anat. 1994 Apr;184 ( Pt 2):407-17 [8014132.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14827-32 [8962140.001]
  • [Cites] Am J Surg Pathol. 1997 Oct;21(10):1144-55 [9331286.001]
  • [Cites] Am J Surg Pathol. 1999 Jun;23(6):617-35 [10366144.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):19-25 [15389251.001]
  • [Cites] Hum Pathol. 2005 Feb;36(2):170-9 [15754294.001]
  • [Cites] Int J Gynecol Pathol. 2006 Jan;25(1):83-9 [16306790.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):97-105 [16294196.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1130-9 [16931958.001]
  • [Cites] Mod Pathol. 2000 Sep;13(9):962-72 [11007036.001]
  • (PMID = 19694825.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA75123; United States / NCI NIH HHS / CA / R01 CA075123-04; United States / NCI NIH HHS / CA / R01 CA095026-04; United States / NCI NIH HHS / CA / R01 CA095026; United States / NCI NIH HHS / CA / CA95026; United States / NCI NIH HHS / CA / R01 CA075123
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Peptide; EC 4.6.1.2 / Guanylate Cyclase; EC 4.6.1.2 / Receptors, Guanylate Cyclase-Coupled; EC 4.6.1.2 / enterotoxin receptor
  • [Other-IDs] NLM/ NIHMS309367; NLM/ PMC3140017
  •  go-up   go-down


Advertisement
4. Dahlstedt E, Collins HA, Balaz M, Kuimova MK, Khurana M, Wilson BC, Phillips D, Anderson HL: One- and two-photon activated phototoxicity of conjugated porphyrin dimers with high two-photon absorption cross sections. Org Biomol Chem; 2009 Mar 7;7(5):897-904
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These dimers demonstrate high one-photon PDT efficacy against a human ovarian adenocarcinoma cell line (SK-OV-3) and exhibit no significant dark-toxicity at concentrations of up to 20 microM.
  • [MeSH-minor] Cell Line, Tumor. Dimerization. Female. Humans. Infrared Rays. Ovarian Neoplasms / therapy. Photons. Photosensitizing Agents / pharmacology. Solubility

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19225672.001).
  • [ISSN] 1477-0539
  • [Journal-full-title] Organic & biomolecular chemistry
  • [ISO-abbreviation] Org. Biomol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin
  •  go-up   go-down


5. Murdoch WJ: Carcinogenic potential of ovulatory genotoxicity. Biol Reprod; 2005 Oct;73(4):586-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ovulation is a rate-limiting event for the perpetuation of a species; unfortunately, it imparts a cancer risk.
  • Reactive oxidants generated during the mechanics of ovulatory follicular rupture damage the DNA of ovarian surface epithelial cells that are located within a limited diffusion radius.
  • Those cells that survive the trauma of ovulation, along the margins of a ruptured follicle, proliferate and migrate to reconcile the discontinuity within the ovarian epithelium created at the site of oocyte release.
  • It is conceivable that clonal expansion of an ovarian surface epithelial cell with unrepaired DNA, but not committed to death, could be an initiating factor in the etiology of common ovarian cancer.
  • In fact, the majority of cancers of the ovary are derived from the surface epithelium; and circumstances that avert ovulation (oral contraceptive use, pregnancy/lactation) protect against ovarian adenocarcinoma.
  • Recent experimental evidence indicates that vitamin E and progesterone protect against ovarian metaplasia by negating the oxidative stress of ovulation and by enhancing the repair capacity (genomic integrity) of the surface epithelium, respectively.
  • Ovarian cancer of surface epithelial origin is a deadly insidious disease because it characteristically remains asymptomatic until it has metastasized throughout the abdominal cavity; therefore, prevention is a high priority.
  • [MeSH-major] Ovarian Neoplasms / etiology. Ovulation / physiology
  • [MeSH-minor] Adenocarcinoma / etiology. Adenocarcinoma / pathology. Adenocarcinoma / prevention & control. Animals. Contraceptive Agents, Female / pharmacology. DNA Damage. Epithelial Cells / pathology. Female. Humans. Lactation. Oxidative Stress. Pregnancy. Progesterone / metabolism. Vitamin E / pharmacology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15958727.001).
  • [ISSN] 0006-3363
  • [Journal-full-title] Biology of reproduction
  • [ISO-abbreviation] Biol. Reprod.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-97796; United States / NCRR NIH HHS / RR / RR-016474
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contraceptive Agents, Female; 1406-18-4 / Vitamin E; 4G7DS2Q64Y / Progesterone
  • [Number-of-references] 103
  •  go-up   go-down


6. Murakami Y, Uemura K, Ohge H, Hayashidani Y, Sudo T, Sueda T: Intraductal papillary-mucinous neoplasms and mucinous cystic neoplasms of the pancreas differentiated by ovarian-type stroma. Surgery; 2006 Sep;140(3):448-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary-mucinous neoplasms and mucinous cystic neoplasms of the pancreas differentiated by ovarian-type stroma.
  • This study was intended to clarify clinicopathologic characteristics in IPMNs and MCNs differentiated by ovarian-type stroma.
  • Patients were divided into IPMN (n = 70) or MCN (n = 7) according to the presence of ovarian-type stroma, and clinicopathologic parameters were compared between groups.
  • RESULTS: IPMNs consisted of 32 adenomas, 12 borderline neoplasms, 13 adenocarcinomas in situ, and 13 invasive adenocarcinomas; MCNs included 6 adenomas and 1 invasive adenocarcinoma.
  • CONCLUSIONS: Clinicopathologic differences between IPMN and MCN are much clearer when differentiated by presence of ovarian-type stroma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / pathology. Adenoma / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Stromal Cells / pathology
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Disease Progression. Female. Humans. Male. Middle Aged. Ovary / cytology. Prognosis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surgery. 2007 Apr;141(4):545-6 [17383536.001]
  • (PMID = 16934608.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Devalapally H, Shenoy D, Little S, Langer R, Amiji M: Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model. Cancer Chemother Pharmacol; 2007 Mar;59(4):477-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model.
  • PURPOSE: The objective of this study was to evaluate the anti-tumor efficacy and lack of systemic toxicity of paclitaxel when administered in pH-sensitive poly(ethylene oxide) (PEO)-modified poly(beta-amino ester) (PbAE) nanoparticles in mice bearing human ovarian adenocarcinoma (SKOV-3) xenograft.
  • [MeSH-major] Drug Delivery Systems. Nanoparticles. Ovarian Neoplasms / drug therapy. Paclitaxel / administration & dosage. Polyesters / administration & dosage

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16862429.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA095522; United States / NCI NIH HHS / CA / R01-CA119617
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Polyesters; 24980-41-4 / polycaprolactone; 30IQX730WE / Polyethylene Glycols; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


8. Husein-ElAhmed H, Aneiros-Fernandez J, Arias-Santiago S, Naranjo-Sintes R: Sister Mary Joseph's nodule as a metastasis of ovarian adenocarcinoma. Int J Dermatol; 2010 Sep;49(9):1045-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sister Mary Joseph's nodule as a metastasis of ovarian adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Ovarian Neoplasms / pathology. Sister Mary Joseph's Nodule / secondary. Skin Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20883267.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Vimentin; 0 / WT1 Proteins; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; BG3F62OND5 / Carboplatin; EC 3.4.24.11 / Neprilysin; P88XT4IS4D / Paclitaxel; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Kim KY, Kim SU, Leung PC, Jeung EB, Choi KC: Influence of the prodrugs 5-fluorocytosine and CPT-11 on ovarian cancer cells using genetically engineered stem cells: tumor-tropic potential and inhibition of ovarian cancer cell growth. Cancer Sci; 2010 Apr;101(4):955-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of the prodrugs 5-fluorocytosine and CPT-11 on ovarian cancer cells using genetically engineered stem cells: tumor-tropic potential and inhibition of ovarian cancer cell growth.
  • In the present study, we evaluated whether these GESTECs were capable of migrating to human ovarian cancer cells and examined the potential therapeutic efficacy of the gene-directed enzyme prodrug therapy against ovarian cancer cells in vitro.
  • A modified transwell migration assay was performed to determine the migratory capacity of GESTECs to ovarian cancer cells.
  • GESTECs (HB1.F3.CD or HB1.F3.CE cells) engineered to express a suicide gene (CD or CE) selectively migrated toward ovarian cancer cells.
  • Treatment of human epithelial ovarian cancer cell line (SKOV-3, an ovarian adenocarcinoma derived from the ascites of an ovarian cancer patient) with the prodrugs 5-fluorocytosine (5-FC) or camptothecin-11 (CPT-11) in the presence of HB1.F3.CD or HB1.F3.CE cells resulted in the inhibition of ovarian cancer cell growth.
  • Based on the data presented herein, we suggest that GESTECs expressing CD/CE may have a potent advantage to selectively treat ovarian cancers.
  • [MeSH-major] Antimetabolites / pharmacology. Antineoplastic Agents, Phytogenic / pharmacology. Camptothecin / analogs & derivatives. Flucytosine / pharmacology. Genetic Therapy / methods. Ovarian Neoplasms / therapy. Prodrugs / pharmacology. Stem Cells

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • Hazardous Substances Data Bank. FLUCYTOSINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20704576.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites; 0 / Antineoplastic Agents, Phytogenic; 0 / Prodrugs; 7673326042 / irinotecan; D83282DT06 / Flucytosine; EC 3.5.4.1 / Cytosine Deaminase; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


10. Chu AY, Litzky LA, Pasha TL, Acs G, Zhang PJ: Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol; 2005 Jan;18(1):105-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma.
  • Although immunohistochemistry has proven to be valuable in the differentiation of epithelioid mesothelioma from pulmonary or metastatic adenocarcinoma, no single antibody has demonstrated absolute sensitivity or specificity in making this distinction.
  • Using immunohistochemical analysis with D2-40, a recently available monoclonal antibody that has been used as a lymphatic endothelial marker, we examined 53 cases of mesothelioma, 28 cases of reactive pleura, 30 cases of pulmonary adenocarcinoma, 35 cases of renal cell carcinoma, 26 cases of ovarian serous carcinoma, 16 cases of invasive breast carcinoma, 11 cases of prostatic adenocarcinoma, and seven cases of urothelial carcinoma.
  • In addition, immunohistochemistry using calretinin, cytokeratin 5/6, and WT1 was performed on all cases of mesothelioma, pulmonary adenocarcinoma, ovarian serous carcinoma, and renal cell carcinoma.
  • Predominantly, membranous D2-40 immunoreactivity was present in 51 of 53 (96%) mesotheliomas, 27 of 28 (96%) cases of reactive pleura, and 17 of 26 (65%) ovarian serous carcinomas; membranous staining was not seen in any other tumors examined.
  • We conclude that D2-40 immunoreactivity is sensitive for cells of mesothelial origin, and may be useful in the differential diagnosis of epithelioid malignant mesothelioma vs adenocarcinoma.
  • [MeSH-major] Antibodies, Monoclonal. Biomarkers, Tumor. Mesothelioma / diagnosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15389250.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / monoclonal antibody D2-40; 0 / oncofetal antigens
  •  go-up   go-down


11. Solár P, Horváth V, Kleban J, Koval' J, Solárová Z, Kozubík A, Fedorocko P: Hsp90 inhibitor geldanamycin increases the sensitivity of resistant ovarian adenocarcinoma cell line A2780cis to cisplatin. Neoplasma; 2007;54(2):127-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hsp90 inhibitor geldanamycin increases the sensitivity of resistant ovarian adenocarcinoma cell line A2780cis to cisplatin.
  • Ovarian carcinoma is the leading cause of death among gynecological neoplasms in the world.
  • The chemoresistance is a major obstacle in the effective treatment of ovarian and other cancers.
  • We evaluated the effects of Hsp90 inhibitor geldanamycin (GEL) alone and in combination with cisplatin in cisplatin resistant ovarian adenocarcinoma cell line.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Benzoquinones / pharmacology. Cisplatin / pharmacology. Drug Resistance, Neoplasm. Enzyme Inhibitors / pharmacology. HSP90 Heat-Shock Proteins / antagonists & inhibitors. Lactams, Macrocyclic / pharmacology. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Blotting, Western. Cell Cycle / drug effects. Cell Proliferation / drug effects. Female. Humans. Tumor Cells, Cultured / drug effects

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17319785.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzoquinones; 0 / Enzyme Inhibitors; 0 / HSP90 Heat-Shock Proteins; 0 / Lactams, Macrocyclic; Q20Q21Q62J / Cisplatin; Z3K3VJ16KU / geldanamycin
  •  go-up   go-down


12. Sakai Y, Hatano B: Metastatic duodenal carcinoma simulating primary mucinous tumor of the ovary. Arch Gynecol Obstet; 2005 Jun;272(1):84-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic duodenal carcinoma simulating primary mucinous tumor of the ovary.
  • CASE REPORT: We report a case of metastatic duodenal carcinoma simulating a primary ovarian mucinous tumor, occurring in a 53-year-old woman who had undergone pancreatoduodenectomy for duodenal adenocarcinoma approximately 18 months previously.
  • The surgically removed bilateral ovaries revealed multicystic tumors.
  • Histological examination showed they closely mimicked primary ovarian mucinous tumors.
  • Immunohistochemical examination using cytokeratin 7 and 20, and CA125 indicated that the bilateral ovarian tumors were metastasis from duodenal carcinoma.
  • CONCLUSIONS: Duodenal carcinoma can be a rare primary focus of metastatic tumor simulating primary ovarian neoplasm.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / secondary. Duodenal Neoplasms / surgery. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / secondary
  • [MeSH-minor] Chemotherapy, Adjuvant. Diagnosis, Differential. Fallopian Tubes / surgery. Female. Humans. Immunohistochemistry. Middle Aged. Ovariectomy. Pancreaticoduodenectomy. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15300447.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


13. Wamunyokoli FW, Bonome T, Lee JY, Feltmate CM, Welch WR, Radonovich M, Pise-Masison C, Brady J, Hao K, Berkowitz RS, Mok S, Birrer MJ: Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance. Clin Cancer Res; 2006 Feb 1;12(3 Pt 1):690-700
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance.
  • PURPOSE: To elucidate the molecular mechanisms contributing to the unique clinicopathologic characteristics of mucinous ovarian carcinoma, global gene expression profiling of mucinous ovarian tumors was carried out.
  • Hierarchical clustering and binary tree prediction analysis were used to determine the relationships among mucinous specimens and a series of previously profiled microdissected serous tumors and normal ovarian surface epithelium.
  • RESULTS: Comparison of the gene profiles between mucinous tumors and normal ovarian epithelial cells identified 1,599, 2,916, and 1,765 differentially expressed in genes in the cystadenomas, LMP tumors, and adenocarcinomas, respectively.
  • Furthermore, the cystadenomas coexpressed a subset of genes that were differentially regulated in LMP and adenocarcinoma specimens compared with normal ovarian surface epithelium.
  • PathwayAssist highlighted pathways with expression of genes involved in drug resistance in both LMP and adenocarcinoma samples.
  • CONCLUSIONS: These data provide a useful basis for understanding the molecular events leading to the development and progression of mucinous ovarian cancer.
  • [MeSH-major] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology
  • [MeSH-minor] Cluster Analysis. Decision Trees. Diagnosis, Differential. Female. Humans. Oligonucleotide Array Sequence Analysis / methods. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16467078.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA165009; United States / NCI NIH HHS / CA / R33CA103595; United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


14. Scott H, Griffin D: Ovarian cancer complicated by invasive pulmonary aspergillus. Gynecol Oncol; 2006 Jan;100(1):216-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian cancer complicated by invasive pulmonary aspergillus.
  • CASE: A 59-year-old woman developed invasive pulmonary aspergillus after surgical debulking of an advanced ovarian adenocarcinoma and initiation of adjuvant combination chemotherapy.
  • CONCLUSION: Invasive pulmonary aspergillus is rarely diagnosed in patients with solid tumors such as ovarian cancer.
  • Successful treatment of the infection relies upon prompt diagnosis and utilization of effective antifungal medications for a prolonged period of time.
  • [MeSH-major] Aspergillosis / etiology. Cystadenocarcinoma, Serous / microbiology. Lung Diseases, Fungal / etiology. Ovarian Neoplasms / microbiology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16169576.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. McCluggage WG, Hurrell DP, Kennedy K: Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ: report of a series of cases. Am J Surg Pathol; 2010 May;34(5):735-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ: report of a series of cases.
  • A variety of other neoplasms rarely metastasize to the cervix and, in most cases, the diagnosis is straightforward because of a combination of clinical and pathologic parameters, common features of metastatic carcinoma within the cervix including predominant involvement of the deep stroma, absence of surface involvement and of an in situ component, and prominent lymphovascular permeation.
  • We describe 6 cases of metastatic adenocarcinoma involving the cervix with superficial "mucosal" involvement mimicking primary cervical adenocarcinoma or adenocarcinoma in situ.
  • In 5 cases, the primary adenocarcinoma was in the ovary or peritoneum and was of serous (4 cases) or clear-cell (1 case) type.
  • In the other case, the primary neoplasm was in the pancreas and this was initially interpreted as a primary cervical adenocarcinoma.
  • In the cases of primary ovarian or peritoneal carcinoma, the mucosal tumor within the cervix, which was discovered at the same time as the ovarian or peritoneal neoplasm, raised the possibility of synchronous independent lesions or metastasis from the cervix to the ovary or peritoneum.
  • In those cases with an ovarian or peritoneal primary, the likely pathogenesis of the cervical involvement is transtubal and intrauterine spread.
  • It is important for the pathologist to be aware of the possibility of cervical mucosal metastasis to avoid an erroneous diagnosis of a primary cervical adenocarcinoma or adenocarcinoma in situ.
  • [MeSH-major] Carcinoma in Situ / diagnosis. Cystadenocarcinoma, Serous / diagnosis. Ovarian Neoplasms / diagnosis. Pancreatic Neoplasms / diagnosis. Peritoneal Neoplasms / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Middle Aged


16. Tassi RA, Bignotti E, Falchetti M, Ravanini M, Calza S, Ravaggi A, Bandiera E, Facchetti F, Pecorelli S, Santin AD: Claudin-7 expression in human epithelial ovarian cancer. Int J Gynecol Cancer; 2008 Nov-Dec;18(6):1262-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Claudin-7 expression in human epithelial ovarian cancer.
  • Claudin-7 (CLDN-7) is a tight junction protein recently found highly differentially expressed in ovarian carcinoma.
  • To evaluate its potential as a novel biomarker, in this study, we quantified and compared claudin-7 expression at messenger RNA and protein level in 110 patients harboring various histologic types of epithelial ovarian carcinomas (EOC).
  • CLDN-7 transcript was found significantly overexpressed in both primary and metastatic EOCs compared to normal human ovarian surface epithelium cell lines (fold change = 111.4, P < 0.001) by reverse transcription-polymerase chain reaction.
  • At the protein level, CLDN-7 expression was found significantly higher in tumors of primary and metastatic origin when compared to normal ovaries (P < 0.001), regardless of the histologic type, the grade of differentiation, and the pathologic stage of the disease (P = 0.12).
  • CLDN-7 is significantly overexpressed in all main histologic types of EOC and in single neoplastic cells disseminated in peritoneal cavity and pleural effusions, suggesting its potential role as novel diagnostic marker in ovarian cancer.
  • Despite widespread expression of CLDN-7 in several human normal tissues, the high density of CLDN-7 molecules, their membranous localization on EOC cells, and their lack of expression on the celomic epithelium in the peritoneal cavity suggest that this target could be potentially suitable for antibody-mediated localized therapies of ovarian adenocarcinoma.
  • [MeSH-major] Gene Expression Regulation, Neoplastic / genetics. Membrane Proteins / metabolism. Ovarian Neoplasms / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18298564.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CLDN7 protein, human; 0 / Claudins; 0 / Membrane Proteins
  •  go-up   go-down


17. Bing Z, Adegboyega PA: Metastasis of small cell carcinoma of lung into an ovarian mucinous neoplasm: immunohistochemistry as a useful ancillary technique for diagnosis and classification of rare tumors. Appl Immunohistochem Mol Morphol; 2005 Mar;13(1):104-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of small cell carcinoma of lung into an ovarian mucinous neoplasm: immunohistochemistry as a useful ancillary technique for diagnosis and classification of rare tumors.
  • The authors report the first case of ovarian mucinous adenocarcinoma with metastasis from a synchronous small cell neuroendocrine carcinoma of the lung.
  • A large, multiloculated cystic mass was found arising from the right ovary.
  • Microscopic examination disclosed a mucinous neoplasm with both mucinous cystadenoma and mucinous papillary adenocarcinoma components.
  • This case, in addition to being the first reported case of such metastasis, also highlights the diagnostic utility of immunohistochemistry as a reliable and very useful ancillary technique for the diagnosis of neoplasms with unusual clinical and/or histomorphologic presentations.

  • Genetic Alliance. consumer health - Ovarian small cell carcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15722802.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromogranins; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; EC 1.11.1.- / Peroxidases
  •  go-up   go-down


18. Jiang J, Chen W, Zhuang R, Song T, Li P: The effect of endostatin mediated by human mesenchymal stem cells on ovarian cancer cells in vitro. J Cancer Res Clin Oncol; 2010 Jun;136(6):873-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of endostatin mediated by human mesenchymal stem cells on ovarian cancer cells in vitro.
  • To investigate the impact of secreted endostatin on cancer cells, SKOV3 cells were co-cultured with MSC-EN cells in Millicell for 48 h, then apoptosis and cell cycle were analyzed on a flow cytometer.
  • CONCLUSION: We found that MSCs possessed great migratory capacity in vitro and the human ovarian adenocarcinoma cell line SKOV3 could significantly induce the migration of MSCs.
  • [MeSH-major] Adenocarcinoma / therapy. Angiogenesis Inhibitors / pharmacology. Apoptosis / drug effects. Endostatins / pharmacology. Genetic Therapy / methods. Mesenchymal Stromal Cells. Ovarian Neoplasms / therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 2004 Nov;25(5):1267-71 [15492814.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3792-803 [12228199.001]
  • [Cites] Nat Med. 2004 Aug;10(8):858-64 [15235597.001]
  • [Cites] Acta Oncol. 2004;43(2):175-81 [15163166.001]
  • [Cites] Science. 2003 Jul 25;301(5632):452-4 [12881543.001]
  • [Cites] Cancer Biol Ther. 2003 Jan-Feb;2(1):48-52 [12673115.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1669-75 [14576065.001]
  • [Cites] Ann Surg Oncol. 2008 Dec;15(12):3601-8 [18818971.001]
  • [Cites] Int J Hematol. 2007 Jul;86(1):8-16 [17675260.001]
  • [Cites] FASEB J. 2007 Oct;21(12):3153-61 [17513560.001]
  • [Cites] Nat Med. 2003 Jun;9(6):702-12 [12778169.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3603-8 [12097260.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Gene Ther. 2005 Jan;12(1):30-8 [15550927.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100 Suppl 1:11917-23 [13679583.001]
  • [Cites] Int J Gynecol Cancer. 2000 Jan;10(S1):33-37 [11240730.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Chin Med J (Engl). 2005 Feb 20;118(4):296-301 [15740667.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4319-28 [16618757.001]
  • [Cites] J Neurosci Res. 2000 Aug 15;61(4):364-70 [10931522.001]
  • [Cites] Semin Oncol. 2006 Dec;33(6 Suppl 12):S25-6 [17223447.001]
  • [Cites] APMIS. 2004 Jul-Aug;112(7-8):496-507 [15563312.001]
  • [Cites] J Cell Sci. 2005 Oct 1;118(Pt 19):4343-52 [16144866.001]
  • [Cites] Int J Exp Pathol. 2002 Dec;83(6):265-74 [12657135.001]
  • [Cites] Exp Cell Res. 2006 Mar 10;312(5):594-607 [16376330.001]
  • [Cites] APMIS. 2003 Nov;111(11):1011-8 [14629267.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3772-84 [12228197.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7669-74 [11606410.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):3967-79 [15899784.001]
  • [Cites] Cell. 1997 Jan 24;88(2):277-85 [9008168.001]
  • [Cites] Hematology. 2002 Apr;7(2):113-7 [12186702.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1835-42 [15014038.001]
  • [Cites] Leukemia. 2005 Jul;19(7):1118-27 [15902288.001]
  • [Cites] Circulation. 2002 Jan 1;105(1):93-8 [11772882.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2396-402 [11588036.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8 [12516034.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1290-8 [16731762.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1259-67 [15709197.001]
  • [Cites] J Natl Cancer Inst. 2004 Nov 3;96(21):1593-603 [15523088.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5789-97 [17575146.001]
  • [Cites] Science. 1999 Apr 2;284(5411):143-7 [10102814.001]
  • [Cites] Gynecol Obstet Invest. 2000;50(4):269-74 [11093052.001]
  • [Cites] Life Sci. 2005 Aug 5;77(12):1331-40 [15936041.001]
  • [Cites] Hum Gene Ther. 2003 Jul 1;14(10):997-1008 [12869217.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3307-18 [15833864.001]
  • [Cites] J Orthop Sci. 2007 Nov;12(6):562-7 [18040639.001]
  • [Cites] Adv Cancer Res. 2005;94:197-229 [16096002.001]
  • (PMID = 19921255.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Endostatins
  •  go-up   go-down


19. Nofech-Mozes S, Ghorab Z, Ismiil N, Ackerman I, Thomas G, Barbera L, Covens A, Khalifa MA: Endometrial endometrioid adenocarcinoma: a pathologic analysis of 827 consecutive cases. Am J Clin Pathol; 2008 Jan;129(1):110-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial endometrioid adenocarcinoma: a pathologic analysis of 827 consecutive cases.
  • We reviewed 827 consecutive cases of pure endometrial endometrioid adenocarcinoma (EEA) treated by hysterectomy to update the distribution of pathologic features.
  • Tumor grade (reported in a 2-tiered system), depth of myometrial invasion, presence of cervical involvement, lymphovascular invasion (LVI), and evidence of extrauterine disease were recorded.The median age at diagnosis was 62 years (range, 30-94 years).
  • Lymph nodes (sampled in 85 cases) were positive in 13 (1.6%), and ovarian metastases were present in 15 cases (1.8%).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymph Nodes / pathology. Middle Aged. Myometrium / pathology. Neoplasm Invasiveness. Ovarian Neoplasms / secondary. Ovary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18089496.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Liscovitch M, Ravid D: A case study in misidentification of cancer cell lines: MCF-7/AdrR cells (re-designated NCI/ADR-RES) are derived from OVCAR-8 human ovarian carcinoma cells. Cancer Lett; 2007 Jan 8;245(1-2):350-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case study in misidentification of cancer cell lines: MCF-7/AdrR cells (re-designated NCI/ADR-RES) are derived from OVCAR-8 human ovarian carcinoma cells.
  • Multidrug-resistant MCF-7 breast adenocarcinoma cells (originally named MCF-7/AdrR cells and later re-designated NCI/ADR-RES) have served as an important and widely used research tool during the last two decades.
  • The results of these analyses, recently posted on the Web, show that NCI/ADR-RES cells are derived from OVCAR-8 ovarian adenocarcinoma cells.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Antibiotics, Antineoplastic / pharmacology. Cell Line, Tumor. Clone Cells / metabolism. Female. Gene Expression Profiling. Humans. Mutation. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology. Tumor Suppressor Protein p53 / genetics


21. Saglam A, Bozdag G, Kuzey GM, Kuçukali T, Ayhan A: Four synchronous female genital malignancies: the ovary, cervix, endometrium and fallopian tube. Arch Gynecol Obstet; 2008 Jun;277(6):557-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four synchronous female genital malignancies: the ovary, cervix, endometrium and fallopian tube.
  • OBJECTIVE: To present a unique case of a 63 year-old woman with coexistent adenocarcinoma of the ovary, endometrium, cervix and fallopian tube.
  • The frozen section of the mass on the right adnex revealed malign mucinous carcinoma of the ovary.
  • As usual, optimal debulking was performed as initial surgical staging procedure of ovarian cancer.
  • The microscopic examination of the right ovary revealed a typical mucinous cystadenocarcinoma.
  • The pale infiltrative lesion in the cervix also turned out to be an adenocarcinoma of the endocervical type with deep stromal invasion and areas of diffuse glandular dysplasia and in-situ glandular neoplasia at the periphery.
  • Besides, several sections from the left fallopian tube uncovered diffuse dysplasia in the lining epithelium and a focus of adenocarcinoma with papillary and cribriform pattern.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Fallopian Tube Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Uterine Cervical Neoplasms / pathology


22. Wood B, Sterrett G, Frost F, Swarbrick N: Diagnosis of extramammary malignancy metastatic to the breast by fine needle biopsy. Pathology; 2008 Jun;40(4):345-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of extramammary malignancy metastatic to the breast by fine needle biopsy.
  • RESULTS: The 32 cases included metastases from a wide range of sites, including cutaneous melanoma (10), lung (8), non-Hodgkin's lymphoma (5), soft tissue (4), colon (2), endometrium, ovary and bladder.
  • The cytological features allow metastatic disease to be suspected in half of the cases, although in the others, particularly patients with metastatic adenocarcinoma, diagnosis without recourse to immunohistochemistry is difficult or impossible.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / secondary. Lung Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology. Melanoma / secondary. Skin Neoplasms / pathology


23. Christie DR, Shaikh FM, Lucas JA 4th, Lucas JA 3rd, Bellis SL: ST6Gal-I expression in ovarian cancer cells promotes an invasive phenotype by altering integrin glycosylation and function. J Ovarian Res; 2008 Oct 01;1(1):3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ST6Gal-I expression in ovarian cancer cells promotes an invasive phenotype by altering integrin glycosylation and function.
  • BACKGROUND: Ovarian adenocarcinoma is not generally discovered in patients until there has been widespread intraperitoneal dissemination, which is why ovarian cancer is the deadliest gynecologic malignancy.
  • Our laboratory has previously shown that the Golgi glycosyltransferase, ST6Gal-I, mediates the hypersialylation of beta1 integrins in colon adenocarcinoma, which leads to a more metastatic tumor cell phenotype.
  • Interestingly, ST6Gal-I mRNA is known to be upregulated in metastatic ovarian cancer, therefore the goal of the present study was to determine whether ST6Gal-I confers a similarly aggressive phenotype to ovarian tumor cells.
  • METHODS: Three ovarian carcinoma cell lines were screened for ST6Gal-I expression, and two of these, PA-1 and SKOV3, were found to produce ST6Gal-I protein.
  • CONCLUSION: ST6Gal-I mediated sialylation of beta1 integrins in ovarian cancer cells may contribute to peritoneal metastasis by altering tumor cell adhesion and migration through extracellular matrix.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 2005;69(5):436-44 [16319516.001]
  • [Cites] Clin Exp Metastasis. 2000;18(1):67-75 [11206841.001]
  • [Cites] Clin Exp Metastasis. 2004;21(8):685-97 [16035613.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4645-52 [15930282.001]
  • [Cites] Glycobiology. 1999 Oct;9(10):1003-8 [10521536.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2253-9 [9605774.001]
  • [Cites] Gynecol Oncol. 1999 Jun;73(3):362-7 [10366461.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 11;96(10):5722-7 [10318951.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1525-37 [10329605.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):243-7 [10188726.001]
  • [Cites] Oncology. 1999;56(2):89-96 [9949292.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4066-70 [9751611.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1997;254(9-10):437-41 [9438113.001]
  • [Cites] Biochim Biophys Acta. 1998 Jan 8;1379(1):23-8 [9468328.001]
  • [Cites] Cancer Res. 1997 Oct 1;57(19):4249-56 [9331085.001]
  • [Cites] FEBS Lett. 1997 Jun 16;409(3):347-50 [9224687.001]
  • [Cites] Int J Cancer. 1996 Sep 17;67(6):826-30 [8824555.001]
  • [Cites] J Biol Chem. 1994 Apr 8;269(14):10637-43 [8144653.001]
  • [Cites] Eur J Biochem. 1993 Jan 15;211(1-2):135-40 [7678804.001]
  • [Cites] Glycobiology. 1992 Feb;2(1):49-56 [1550989.001]
  • [Cites] J Biol Chem. 1990 Oct 15;265(29):17849-53 [2211665.001]
  • [Cites] Br J Cancer. 1991 Oct;64(4):617-20 [1911209.001]
  • [Cites] Eur J Biochem. 2004 Sep;271(18):3623-34 [15355339.001]
  • [Cites] Biochim Biophys Acta. 2004 May 27;1663(1-2):52-60 [15157607.001]
  • [Cites] Oncogene. 2003 Oct 16;22(46):7137-45 [14562042.001]
  • [Cites] Hybridoma. 2000 Aug;19(4):281-6 [11001400.001]
  • [Cites] Mol Cell Biol Res Commun. 2000 Jan;3(1):48-52 [10683317.001]
  • [Cites] Glycobiology. 2007 Dec;17(12):1344-56 [17884841.001]
  • [Cites] Lab Invest. 2007 Sep;87(9):851-7 [17632542.001]
  • [Cites] J Cell Biol. 2006 Mar 27;172(7):973-81 [16567498.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):369-75 [16428474.001]
  • [Cites] World J Gastroenterol. 2005 Nov 14;11(42):6701-6 [16425369.001]
  • [Cites] Gynecol Oncol. 2003 Jun;89(3):395-401 [12798701.001]
  • [Cites] Clin Exp Metastasis. 2003;20(2):143-52 [12705635.001]
  • [Cites] Med Res Rev. 2003 Jan;23(1):32-47 [12424752.001]
  • [Cites] J Biol Chem. 2002 Sep 6;277(36):32830-6 [12091385.001]
  • [Cites] Exp Cell Res. 2002 May 15;276(1):101-10 [11978012.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2071-80 [11733357.001]
  • [Cites] Biochim Biophys Acta. 2001 May 31;1536(2-3):148-60 [11406350.001]
  • [Cites] Glycoconj J. 2000 Oct;17(10):669-76 [11425186.001]
  • [Cites] Gynecol Oncol. 2005 Dec;99(3):631-9 [16112178.001]
  • (PMID = 19014651.001).
  • [ISSN] 1757-2215
  • [Journal-full-title] Journal of ovarian research
  • [ISO-abbreviation] J Ovarian Res
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA084248
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2584051
  •  go-up   go-down


24. Suzuki N, Yoshioka N, Uekawa A, Matsumura N, Tozawa A, Koike J, Konishi I, Kiguchi K, Ishizuka B: Transcription factor POU6F1 is important for proliferation of clear cell adenocarcinoma of the ovary and is a potential new molecular target. Int J Gynecol Cancer; 2010 Feb;20(2):212-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcription factor POU6F1 is important for proliferation of clear cell adenocarcinoma of the ovary and is a potential new molecular target.
  • OBJECTIVE: Clear cell adenocarcinoma of the ovary often shows resistance to anticancer agents.
  • It accounts for 20% of epithelial ovarian cancer in Japan versus around 5% in other countries.
  • We investigated new molecules to use when developing molecular-targeting therapy for clear cell adenocarcinoma.
  • METHODS: Reverse transcriptase polymerase chain reaction and Western blot analysis were performed to confirm the expression of POU6F1 in several kinds of cell lines derived from epithelial ovarian carcinoma.
  • Microarray analyses were performed using 2 ovarian cancer microarray data sets available on the Internet.
  • Immunohistochemical staining was also done to confirm both the expression and the localization of POU6F1 using human ovarian epithelial ovarian carcinoma tissue specimens.
  • In addition, the gene cluster located downstream of transcription factor POU6F1 was investigated to analyze its role in the proliferation of clear cell adenocarcinoma of the ovary via the lysophosphatidic acid receptor, a G protein-coupled receptor.
  • Furthermore, RNA interference studies with small interfering RNA (siRNA) were performed to assess the effect of POU6F1 on proliferation of xenograft tumors after injection of clear cell adenocarcinoma cells into nude mice.
  • RESULTS: Expression of POU6F1 at messenger RNA and protein was confirmed in cell lines derived from epithelial ovarian carcinoma.
  • The microarray analyses performed using the 2 ovarian cancer microarray data sets available on the Internet indicated that POU6F1 expression was significantly greater in clear cell adenocarcinoma.
  • Immunostaining confirmed the nuclear localization of POU6F1 in clear cell adenocarcinoma (100%).
  • POU6F1 siRNA dose-dependently suppressed the proliferation of clear cell adenocarcinoma cell lines, and a similar effect was confirmed for tumors transplanted into nude mice.
  • CONCLUSIONS: Clear cell adenocarcinoma shows little response to standard therapy.
  • The results of this study suggested that the transcription factor POU6F1 could be a new molecular target for treatment of this cancer.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Ovarian Neoplasms / metabolism. POU Domain Factors / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20134265.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Multienzyme Complexes; 0 / POU Domain Factors; 0 / POU6F1 protein, human; 0 / RNA, Small Interfering; 0 / Receptors, Lysophosphatidic Acid; EC 3.1.4.- / Phosphoric Diester Hydrolases; EC 3.1.4.1 / Phosphodiesterase I; EC 3.1.4.39 / alkylglycerophosphoethanolamine phosphodiesterase; EC 3.6.1.- / Pyrophosphatases
  •  go-up   go-down


25. Van Holsbeke C, Van Belle V, Leone FP, Guerriero S, Paladini D, Melis GB, Greggi S, Fischerova D, De Jonge E, Neven P, Bourne T, Valentin L, Van Huffel S, Timmerman D: Prospective external validation of the 'ovarian crescent sign' as a single ultrasound parameter to distinguish between benign and malignant adnexal pathology. Ultrasound Obstet Gynecol; 2010 Jul;36(1):81-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective external validation of the 'ovarian crescent sign' as a single ultrasound parameter to distinguish between benign and malignant adnexal pathology.
  • OBJECTIVE: To determine the sensitivity and specificity of the 'ovarian crescent sign' (OCS)-a rim of normal ovarian tissue seen adjacent to an ipsilateral adnexal mass-as a sonographic feature to discriminate between benign and malignant adnexal masses.
  • METHODS: The patients included were a subgroup of patients participating in the International Ovarian Tumor Analysis (IOTA) Phase 2 study, which is an international multicenter study.
  • The gold standard was the histological diagnosis of the adnexal mass.
  • The OCS was present in 398 (42%) of 938 benign masses, in 14 (16%) of 86 borderline tumors, in 18 (6%) of 305 primary invasive tumors (one malignant struma ovarii, one uterine clear cell adenocarcinoma and 16 epithelial carcinomas, i.e. four Stage I and 12 Stage II-IV) and in two (4%) of 48 ovarian metastases.
  • [MeSH-major] Ovarian Neoplasms / ultrasonography. Ovary / ultrasonography
  • [MeSH-minor] Adnexal Diseases / ultrasonography. Diagnosis, Differential. Female. Humans. Neoplasm Staging. Predictive Value of Tests. Prospective Studies. Sensitivity and Specificity. Ultrasonography, Doppler

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 ISUOG. Published by John Wiley & Sons, Ltd.
  • (PMID = 20217895.001).
  • [ISSN] 1469-0705
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  •  go-up   go-down


26. Vang R, Gown AM, Zhao C, Barry TS, Isacson C, Richardson MS, Ronnett BM: Ovarian mucinous tumors associated with mature cystic teratomas: morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encountered as secondary tumors in the ovary. Am J Surg Pathol; 2007 Jun;31(6):854-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian mucinous tumors associated with mature cystic teratomas: morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encountered as secondary tumors in the ovary.
  • Most primary ovarian mucinous tumors are of surface epithelial-stromal origin and exhibit diffuse expression of cytokeratin 7 (CK7) combined with variable expression of cytokeratin 20 (CK20); this immunoprofile distinguishes them from most lower gastrointestinal tract tumors secondarily involving the ovaries.
  • The uncommon ovarian mucinous tumors of germ cell (teratomatous) origin have not been extensively evaluated to determine the utility of these markers and other markers of intestinal differentiation for distinguishing these tumors from metastatic gastrointestinal tract mucinous tumors.
  • Immunohistochemical expression of CK7, CK20, CDX2, and villin was assessed in 44 ovarian mucinous tumors associated with a mature cystic teratoma.
  • In practice, the more common diagnosis of secondary involvement by a lower intestinal tract mucinous tumor should be addressed in the pathology report and in subsequent clinical evaluation; interpretation as a true primary ovarian mucinous tumor of teratomatous origin can be considered as an alternative diagnosis when evaluation and follow-up fail to identify a nonovarian source of the mucinous tumor.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / secondary. Gastrointestinal Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Teratoma / pathology
  • [MeSH-minor] Biomarkers, Tumor. Diagnosis, Differential. Female. Homeodomain Proteins / metabolism. Humans. Immunohistochemistry. Keratin-20 / metabolism. Keratin-7 / metabolism. Microfilament Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17527072.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / Keratin-20; 0 / Keratin-7; 0 / Microfilament Proteins; 0 / villin
  •  go-up   go-down


27. Devalapally H, Duan Z, Seiden MV, Amiji MM: Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer. Int J Cancer; 2007 Oct 15;121(8):1830-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer.
  • Subcutaneous sensitive (wild-type) and multidrug resistant (MDR-1 positive) SKOV-3 human ovarian adenocarcinoma xenografts were established in female Nu/Nu mice.
  • The results of this study show that combination of PTX and CER in biodegradable polymeric nanoparticles can serve as a very effective therapeutic strategy to overcome drug resistance in ovarian cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / administration & dosage. Ceramides / administration & dosage. Drug Resistance, Neoplasm. Nanoparticles. Ovarian Neoplasms / drug therapy. Paclitaxel / administration & dosage. Polyesters

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17557285.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA119617
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Biocompatible Materials; 0 / Ceramides; 0 / N-(alpha-hydroxyoctadecanoyl)phytosphingosine; 0 / Polyesters; 0 / polyethylene oxide-polycaprolactone copolymer; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


28. Wang L, Chang X, Yuan G, Zhao Y, Wang P: Expression of peptidylarginine deiminase type 4 in ovarian tumors. Int J Biol Sci; 2010;6(5):454-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of peptidylarginine deiminase type 4 in ovarian tumors.
  • The current study focused on the expression of PADI4 in various subtypes of ovary cancers, and this study investigated the effects of estrogen on PADI4 expression in SKOV-3 cells that originated from ovary tumors.
  • PADI4 was detected in serious cystadenocarcinoma (n=39, positivity=100%), clear cell cancer (n=7, positivity= 100%), mucinous cystadenocarcinoma (n=6, positivity=100%), dysgerminoma (n=6, positivity=100%), squamous cell tumor (n=6, positivity=100%), sibnet-ring cell carcinoma (n=6, positivity=100%), endodermal sinus tumor (n=6, positivity=100%), germ cell tumors (n=6, positivity=100%) and immature teratoma (n=6, positivity=100%).
  • However, PADI4 was either not detected or detected at low levels in granulosa cell tumor (n=6), malignant thecoma (n=6), ovarian cystadenoma (n=5) and normal ovarian tissue (n=11).
  • In addition, the PADI4 level was positively related with the ages of the patients that presented with serious adenocarcinoma (p=0.029).
  • Real-time PCR and western blot analyses confirmed that PADI4 was expressed at higher levels in ovarian adenocarcinoma (n=8) compared to ovarian cystadenoma (n=5) (p< 0.05).
  • The results suggest an important role for PADI4 in the tumorigenesis of ovary cancers that are under the regulation of estrogen.
  • [MeSH-major] Hydrolases / metabolism. Ovarian Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Rev. 1998 Aug;19(4):397-428 [9715373.001]
  • [Cites] J Biol Chem. 2008 Jul 18;283(29):20060-8 [18499678.001]
  • [Cites] Int Immunol. 1998 Dec;10(12):1891-5 [9885910.001]
  • [Cites] Clin Endocrinol (Oxf). 1998 Dec;49(6):695-707 [10209555.001]
  • [Cites] Rheumatology (Oxford). 2005 Jan;44(1):40-50 [15466895.001]
  • [Cites] Endocrine. 2005 Apr;26(3):297-300 [16034185.001]
  • [Cites] BMC Cancer. 2009;9:40 [19183436.001]
  • [Cites] J Leukoc Biol. 2001 Jul;70(1):46-51 [11435484.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jan 25;290(3):979-83 [11798170.001]
  • [Cites] Oncologist. 2002;7(1):73-81 [11854549.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] J Biol Chem. 2002 Dec 20;277(51):49562-8 [12393868.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1180-9 [12637488.001]
  • [Cites] Ann Rheum Dis. 2004 Apr;63(4):373-81 [15020330.001]
  • [Cites] Cell. 2004 Sep 3;118(5):545-53 [15339660.001]
  • [Cites] Science. 2004 Oct 8;306(5694):279-83 [15345777.001]
  • [Cites] Acta Radiol Oncol. 1980;19(4):241-4 [6257044.001]
  • [Cites] Cancer Surv. 1994;19-20:287-307 [7895220.001]
  • [Cites] Am J Epidemiol. 1995 May 1;141(9):828-35 [7717359.001]
  • [Cites] Mol Carcinog. 2006 Mar;45(3):183-96 [16355400.001]
  • [Cites] Apoptosis. 2006 Feb;11(2):183-96 [16502257.001]
  • [Cites] Mol Endocrinol. 2007 Jul;21(7):1617-29 [17456793.001]
  • [Cites] Hum Reprod Update. 2007 Sep-Oct;13(5):453-63 [17573406.001]
  • [Cites] Gynecol Oncol. 2007 Nov;107(2):266-73 [17698176.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10746-50 [9724775.001]
  • (PMID = 20827398.001).
  • [ISSN] 1449-2288
  • [Journal-full-title] International journal of biological sciences
  • [ISO-abbreviation] Int. J. Biol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / RNA, Messenger; 4TI98Z838E / Estradiol; EC 3.- / Hydrolases; EC 3.5.3.15 / peptidylarginine deiminase type IV
  • [Other-IDs] NLM/ PMC2935668
  • [Keywords] NOTNLM ; Peptidylarginine deiminase type 4 (PADI4/PAD4) / estrodial-17β. / ovarian cancer (OCa)
  •  go-up   go-down


29. Watanabe Y, Tsuchiya H, Sakabe T, Matsuoka S, Akechi Y, Fujimoto Y, Yamane K, Ikeda R, Nishio R, Terabayashi K, Ishii K, Gonda K, Matsumi Y, Ashla AA, Okamoto H, Takubo K, Tomita A, Hoshikawa Y, Kurimasa A, Itamochi H, Harada T, Terakawa N, Shiota G: CD437 induces apoptosis in ovarian adenocarcinoma cells via ER stress signaling. Biochem Biophys Res Commun; 2008 Feb 15;366(3):840-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD437 induces apoptosis in ovarian adenocarcinoma cells via ER stress signaling.
  • A synthetic retinoid, CD437, has been shown to exert potent anti-tumor activity against various types of cancer cell lines, regardless of their sensitivities to natural retinoids.
  • We herein demonstrate that CD437 induces endoplasmic reticulum (ER) stress, including the up-regulation of CHOP, BIP and GADD34 mRNA through ER stress transducer (PERK and IRE1alpha) activation in an ovarian adenocarcinoma cell line, SKOV3.
  • It was also shown that CD437 induced the CHOP and GADD34 expressions in another four ovarian adenocarcinoma cell lines, indicating that CD437 functions as an ER stress inducer in these cell lines.
  • These results suggest that ER stress plays an important role in the mechanism by which CD437 induces apoptosis in ovarian adenocarcinoma cells.
  • [MeSH-major] Adenocarcinoma / metabolism. Apoptosis / drug effects. Endoplasmic Reticulum / metabolism. Ovarian Neoplasms / metabolism. Retinoids / administration & dosage. Signal Transduction / drug effects

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18082618.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CD 437; 0 / Retinoids
  •  go-up   go-down


30. Whitworth MK, Backen AC, Clamp AR, Wilson G, McVey R, Friedl A, Rapraeger AC, David G, McGown A, Slade RJ, Gallagher JT, Jayson GC: Regulation of fibroblast growth factor-2 activity by human ovarian cancer tumor endothelium. Clin Cancer Res; 2005 Jun 15;11(12):4282-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of fibroblast growth factor-2 activity by human ovarian cancer tumor endothelium.
  • We have investigated the relationship among heparan sulfate, FGF-2, and the signal-transducing receptors in human, advanced-stage, serous ovarian adenocarcinoma.
  • This may be taken as a surrogate marker for the distribution of biologically active heparan sulfate and was distributed predominantly in endothelial cells and stroma but was absent from adenocarcinoma cells.
  • The data suggest that the entire extracellular signaling apparatus, consisting of FGF-2, biologically active heparan sulfate, and FGFRs capable of responding to FGF-2, is present in ovarian cancer endothelium, thereby highlighting the cytokine and its cognate receptor as potential targets for the antiangiogenic treatment of this disease.
  • [MeSH-major] Endothelium / pathology. Fibroblast Growth Factor 2 / metabolism. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15958608.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / Receptors, Fibroblast Growth Factor; 0 / Sulfates; 103107-01-3 / Fibroblast Growth Factor 2; 9050-30-0 / Heparitin Sulfate; EC 2.7.10.1 / FGFR1 protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 1; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


31. Rojo Sebastián A, Fernández Morejón FJ, Bretcha Boix P, Farré Alegre J, Forteza Vila J, Brugarolas Masllorens A: Controversial origin of Pseudomyxoma peritonei. Clin Transl Oncol; 2006 Oct;8(10):767-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The main diagnostic problem appears when the primary site of origin could be appendix or ovary.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Appendiceal Neoplasms / pathology. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / etiology. Pseudomyxoma Peritonei / etiology
  • [MeSH-minor] Aged. Appendix / pathology. Diagnosis, Differential. Female. Humans. Ovary / pathology. Peritoneum / pathology. Prognosis

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2003 Aug;27(8):1089-103 [12883241.001]
  • [Cites] Am J Surg Pathol. 1996 Jun;20(6):739-46 [8651354.001]
  • [Cites] Eur J Gynaecol Oncol. 2004;25(4):411-4 [15285293.001]
  • [Cites] Colorectal Dis. 2005 Jul;7(4):382-6 [15932563.001]
  • [Cites] Am J Surg Pathol. 1991 May;15(5):415-29 [2035736.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1849-55 [10362811.001]
  • (PMID = 17074679.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


32. Fanghong Li, Szallasi A, Young RH: Wolffian tumor of the ovary with a prominent spindle cell component: report of a case with brief discussion of unusual problems in differential diagnosis, and literature review. Int J Surg Pathol; 2008 Apr;16(2):222-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wolffian tumor of the ovary with a prominent spindle cell component: report of a case with brief discussion of unusual problems in differential diagnosis, and literature review.
  • An 87-year-old woman underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy for endometrioid adenocarcinoma.
  • At operation, a 4.5-cm partially solid and partially cystic right ovarian mass was identified.
  • Extensive sampling of the ovarian mass revealed a focus with the classic sieve-like pattern of a Wolffian adnexal tumor that merged with the fibroma-like appearance.
  • The uterus showed well-differentiated, superficially invasive endometrioid adenocarcinoma arising in a background of atypical complex hyperplasia.
  • Given the recent reports implying a therapeutic value for Gleevec (Novartis, Stein, Switzerland) (STI-571) in the treatment of Wolffian tumor of the ovary, paraffin immunostain for CD117 (c-kit) was performed that yielded negative results.
  • This case demonstrates the heterogeneity of Wolffian tumor of the ovary and shows how crucial sampling is in arriving at the correct diagnosis.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Fibroma / pathology. Ovarian Neoplasms / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Biomarkers, Tumor / analysis. Diagnosis, Differential. Disease-Free Survival. Female. Humans. Immunohistochemistry. Neoplasms, Multiple Primary / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Wolffian tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18417686.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


33. Zhao C, Florea A, Austin RM: Clinical utility of adjunctive high-risk human papillomavirus DNA testing in women with Papanicolaou test findings of atypical glandular cells. Arch Pathol Lab Med; 2010 Jan;134(1):103-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among the 75 cases with hrHPV+ AGC results, 13 (17.3%) had cervical intraepithelial neoplasia grades 2/3, 10 (13.3%) had adenocarcinoma in situ, and 3 (4.0%) had cervical invasive adenocarcinoma, whereas for 234 women with hrHPV(-) results, 1 (0.4%) had cervical intraepithelial neoplasia grades 2/3, 1 (0.4%) had adenocarcinoma in situ, 1 each (0.4%) had cervical adenocarcinoma and ovarian carcinoma, and 8 (3.4%) had endometrial carcinoma.
  • CONCLUSIONS: Positive hrHPV AGC results were most strongly associated with cervical intraepithelial neoplasia grades 2/3 and adenocarcinoma in situ in women younger than 50 years.
  • Positive hrHPV AGC results were also present in all 3 cases of invasive cervical adenocarcinoma in women younger than 50 years.
  • Of note, hrHPV(-) AGC results were present in 10 of 13 carcinomas (76.9%) detected after AGC Pap tests, all in women 40 years or older with endometrial adenocarcinomas (n = 8), ovarian carcinoma (n = 1), and cervical adenosquamous carcinoma in a woman (n = 1) in her 50s.
  • Testing for hrHPV after AGC Pap testing was most helpful in the detection of cervical intraepithelial neoplasia grades 2/3, adenocarcinoma in situ, and invasive cervical adenocarcinomas in women younger than 50 years.
  • [MeSH-major] Adenocarcinoma / pathology. Cervical Intraepithelial Neoplasia / pathology. DNA, Viral. Papanicolaou Test. Papillomaviridae / genetics. Uterine Cervical Neoplasms / pathology. Vaginal Smears
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Carcinoma in Situ / pathology. Carcinoma in Situ / virology. Endometrial Neoplasms / pathology. Endometrial Neoplasms / virology. Female. Humans. Middle Aged. Ovarian Neoplasms / pathology. Ovarian Neoplasms / virology. Retrospective Studies. Risk Factors. Sensitivity and Specificity. Young Adult


34. Shibahara K, Endo K, Ikeda T, Sakata H, Sadanaga N, Morita M, Kakeji Y, Maehara Y: Colon metastasis 20 years after the removal of ovarian cancer: Report of a case. Surg Today; 2009;39(2):153-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colon metastasis 20 years after the removal of ovarian cancer: Report of a case.
  • This report describes the case of a patient who had undergone surgery to resect bilateral ovarian tumors and then presented with colon metastasis 20 years later.
  • She had been operated on for bilateral ovarian cancer in 1987 and was treated by postoperative adjuvant chemotherapy.
  • A biopsy of the lesion showed a group V, moderately differentiated adenocarcinoma.
  • Immunohistochemical staining during the pathological diagnosis showed the lesion to be colon metastasis from a serous papillary adenocarcinoma of the ovary.
  • The use of immunohistochemistry demonstrated the tumor to be of ovarian origin.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / secondary. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1998 Jul;22(7):805-15 [9669343.001]
  • [Cites] Surg Today. 2002;32(8):750-2 [12181732.001]
  • [Cites] Mod Pathol. 1996 Nov;9(11):1040-4 [8933513.001]
  • [Cites] Acta Chir Belg. 1990 Jul-Aug;90(4):166-71 [2239034.001]
  • [Cites] Am J Clin Oncol. 2000 Apr;23(2):107-16 [10776968.001]
  • [Cites] Jpn J Surg. 1986 Sep;16(5):305-10 [3467109.001]
  • [Cites] Ann Pathol. 1999 Dec;19(6):492-8 [10617806.001]
  • (PMID = 19198996.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


35. Jung JY, Kim YJ, Kim HM, Kim HJ, Park SW, Song SY, Chung JB, Kang CM, Pyo JY, Yang WI, Bang S: Hepatoid carcinoma of the pancreas combined with neuroendocrine carcinoma. Gut Liver; 2010 Mar;4(1):98-102
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common sites of extrahepatic carcinoma are the stomach and ovary, but nine cases of hepatocellular differentiation of the pancreas have been reported in the literature.
  • He underwent a conventional Whipple operation, and light microscopy showed adenocarcinoma that was immunopositive for AFP, hepatocyte antigen, cytokeratin, chromogranin, synaptophysin, and alpha-1 antichymotrypsin.
  • Although hepatoid differentiation was not shown unequivocally histologically, other immunohistochemistry findings supported the diagnosis of hepatoid carcinoma combined with neuroendocrine carcinoma.
  • This report describes why hepatoid carcinoma should be considered as a differential diagnosis of a pancreatic mass, especially when serum AFP is elevated.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2007 Jan;31(1):146-52 [17197931.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1582-9 [10738216.001]
  • [Cites] Am Surg. 2004 Nov;70(11):1030-3 [15586521.001]
  • [Cites] Am J Gastroenterol. 1999 Jun;94(6):1658-63 [10364040.001]
  • [Cites] Mayo Clin Proc. 1997 Dec;72(12):1154-60 [9413299.001]
  • [Cites] Cancer. 1993 Sep 15;72(6):1827-35 [7689918.001]
  • [Cites] Cancer. 1993 Jan 15;71(2):293-6 [7678544.001]
  • [Cites] Hepatogastroenterology. 1992 Jun;39(3):282-6 [1380476.001]
  • [Cites] Cancer. 1986 Jul 1;58(1):119-26 [2423220.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):840-8 [2410093.001]
  • [Cites] Cell Differ. 1986 Mar;18(2):109-17 [3513967.001]
  • [Cites] Am J Clin Pathol. 1987 Nov;88(5):639-45 [3673946.001]
  • [Cites] Lab Invest. 1990 May;62(5):552-61 [2342330.001]
  • [Cites] Ann N Y Acad Sci. 1983;417:105-7 [6200025.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Apr;78(4):2577-81 [6941311.001]
  • [Cites] Cancer Res. 1972 May;32(5):979-82 [4111729.001]
  • [Cites] J Gastroenterol. 2006 Oct;41(10):1011-9 [17096071.001]
  • (PMID = 20479919.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2871600
  • [Keywords] NOTNLM ; Hepatoid carcinoma / Neuroendocrine carcinoma / Pancreas
  •  go-up   go-down


36. Gontier E, Wartski M, Guinebretiere JM, Alberini JL: 18F-FDG PET/CT in a patient with lymph node metastasis from ovarian adenocarcinoma. AJR Am J Roentgenol; 2006 Sep;187(3):W285-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-FDG PET/CT in a patient with lymph node metastasis from ovarian adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Lymphatic Metastasis / radionuclide imaging. Ovarian Neoplasms / radionuclide imaging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16928906.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


37. Young RH: From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II. Adv Anat Pathol; 2007 May;14(3):149-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II.
  • This is the second of a two-part consideration of metastatic tumors to the ovary.
  • The first tumor discussed is gastric carcinoma of intestinal-type whose ovarian manifestations have been the subject of a recent paper which emphasized its differences from the Krukenberg tumor.
  • Coverage of intestinal adenocarcinoma emphasizes the landmark 1987 paper of RH Lash and WR Hart.
  • The section on appendiceal neoplasms highlights ovarian spread of diverse tumors ranging from typical intestinal-type adenocarcinoma to signet-ring cell carcinomas with various patterns which in the ovary may prompt diagnoses such as a goblet cell (mucinous) carcinoid tumor, but whose ovarian features place them in the category of a Krukenberg tumor.
  • The diverse problems in differential diagnosis of carcinoid tumor (provoked by nested, acinar, and other patterns, including folliclelike spaces) are then reviewed.
  • The section on breast cancer emphasizes that, although usually a manifestation of late stage disease and often not bulky in the ovaries, metastatic breast cancer may form large masses which can represent the clinical presentation.
  • That patients with breast cancer have an increased risk of primary ovarian cancer and that the latter is more common than secondary spread of breast cancer is noted.
  • The section on lung tumors largely reflects information in a recent paper that small cell carcinoma and adenocarcinoma are the lung cancers that spread to the ovary most commonly.
  • The extremely broad differential diagnosis posed by metastatic malignant melanoma ranging from that of an oxyphilic tumor, to a small cell tumor, to a follicle-forming neoplasm, is then considered.
  • The sections on renal cell carcinoma and other urinary tract neoplasms emphasize the differential diagnosis of metastatic clear cell carcinoma and primary clear cell carcinoma, an issue usually resolvable by an awareness of the various features of the ovarian variant, rarely or never seen in the renal variant.
  • The endometrial stromal tumors are problematic largely because the history of a primary tumor may be remote, in the ovaries the typical growth and vascular pattern of endometrial stromal neoplasms is not always conspicuous, and some endometrial stromal sarcomas in the ovary show sex cordlike patterns of growth.
  • Recent information has indicated that gastrointestinal stromal tumors may rarely have significant ovarian manifestations and if the primary neoplasm is overlooked, the ovarian tumor may be misdiagnosed, usually as an ovarian fibromatous tumor, but potentially as another primary neoplasm.
  • The sections on ovarian spread of uterine carcinomas emphasize the problems owing to cervical adenocarcinomas, which have a greater tendency to involve the ovaries than squamous cell carcinomas and can simulate primary mucinous or endometrioid cancers.
  • The microscopic features of malignant mesothelioma are so different from those of primary ovarian carcinoma in most instances that the diagnosis should be readily established on routine microscopic evaluation.
  • The differential diagnosis of the desmoplastic small round cell tumor is more complex because of the greater overlap with the many other small cell malignant tumors that may involve the ovaries primarily or secondarily.
  • However, as pointed out in brief concluding remarks, despite the aid of that modality, as in surgical pathology overall, careful consideration of the clinical background, distribution of disease, gross characteristics and spectrum of routine microscopic findings, will lead to the correct diagnosis in the majority of cases and at the very least lead to formulation of a considered differential diagnosis such that use of special techniques may be judicious and those results placed in context of the time-honored clinical and pathologic features.
  • [MeSH-major] Carcinoma / secondary. Krukenberg Tumor / secondary. Ovarian Neoplasms / secondary
  • [MeSH-minor] Diagnosis, Differential. Female. History, 19th Century. History, 20th Century. Humans

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17452813.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 67
  •  go-up   go-down


38. Komiyama S, Nakamura M, Murakami I, Kuwabara Y, Kurahashi T, Tanaka K, Mikami M: A heavily pretreated patient with recurrent clear cell adenocarcinoma of the ovary in whom carcinomatous peritonitis was controlled successfully by salvage therapy with gemcitabine. Arch Gynecol Obstet; 2008 Dec;278(6):565-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A heavily pretreated patient with recurrent clear cell adenocarcinoma of the ovary in whom carcinomatous peritonitis was controlled successfully by salvage therapy with gemcitabine.
  • INTRODUCTION: Advanced clear cell adenocarcinoma of the ovary is a histologic type with an extremely poor prognosis.
  • No reports have been published concerning useful drugs for salvage chemotherapy for this type of cancer.
  • We performed salvage therapy with gemcitabine in a patient with multiple-drug- resistant, unresectable recurrent clear cell adenocarcinoma of the ovary and succeeded in stabilizing recurrent lesions and controlling carcinomatous peritonitis.
  • CASE REPORT: A 55-year-old woman was in Stage IIIc of clear cell adenocarcinoma of the ovary.
  • CONCLUSION: Gemcitabine is also useful for heavily pretreated clear cell adenocarcinoma of the ovary.
  • It is necessary to consider the use of drugs without cross resistance to platinum and taxanes in the selection of drugs for this cancer.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy. Peritonitis / drug therapy. Salvage Therapy / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Arch Gynecol Obstet. 2009 Feb;279(2):271. Komiyama, Shin [corrected to Komiyama, Shin-ichi]
  • (PMID = 17576588.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


39. Sughayer MA, Zakarneh L, Abu-Shakra R: Collision metastasis of breast and ovarian adenocarcinoma in axillary lymph nodes: a case report and review of the literature. Pathol Oncol Res; 2009 Sep;15(3):423-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision metastasis of breast and ovarian adenocarcinoma in axillary lymph nodes: a case report and review of the literature.
  • Despite their accepted clinical and genetic association, the incidence of synchronous breast and ovarian carcinoma is rare.
  • Moreover, collision metastasis from both breast and ovarian carcinomas to the same lymph node, to our knowledge has never been reported.
  • Review of the literature revealed eleven cases of metastatic malignant tumors colliding in the same lymph node, none of which had both ovarian and breast carcinoma.
  • One month later the patient was found to have malignant ascites, omental carcinomatosis and an ovarian mass.
  • Histology and immunohistochemistry revealed high grade serous papillary adenocarcinoma.
  • When surgery was done to treat the breast tumor some of the axillary lymph nodes revealed metastases from the breast primary, others metastases from the ovarian primary and one had both tumors in a collision phenomenon.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Lymphatic Metastasis / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1996 Feb;20(2):245-50 [8554115.001]
  • [Cites] Am J Clin Pathol. 1983 Aug;80(2):228-30 [6349326.001]
  • [Cites] Pathol Int. 1996 Oct;46(10):787-90 [8916150.001]
  • [Cites] Int J Urol. 1997 Mar;4(2):222-4 [9179702.001]
  • [Cites] Dis Colon Rectum. 2005 Feb;48(2):384-9 [15812588.001]
  • [Cites] Science. 1994 Oct 7;266(5182):66-71 [7545954.001]
  • [Cites] Arch Pathol Lab Med. 2004 Mar;128(3):318-20 [14987155.001]
  • [Cites] Int Urol Nephrol. 1995;27(6):743-5 [8725040.001]
  • [Cites] Science. 1994 Sep 30;265(5181):2088-90 [8091231.001]
  • [Cites] Arch Pathol Lab Med. 2001 Oct;125(10):1354-7 [11570915.001]
  • [Cites] J Pathol. 1969 Jan;97(1):143-5 [5783628.001]
  • [Cites] Surg Radiol Anat. 1993;15(2):119-23 [7690160.001]
  • (PMID = 19067238.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Carrier Proteins; 0 / Glycoproteins; 0 / PIP protein, human
  • [Number-of-references] 12
  •  go-up   go-down


40. Moschos SJ, Mo YY: Role of SUMO/Ubc9 in DNA damage repair and tumorigenesis. J Mol Histol; 2006 Sep;37(5-7):309-19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent reports indicate that Ubc9, the single SUMO E2 enzyme catalyzing the conjugation of SUMO to target proteins, is overexpressed in certain tumors, such as lung adenocarcinoma, ovarian carcinoma and melanoma, suggestive of its clinic significance.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 2005 Sep 12;579(22):5007-12 [16122737.001]
  • [Cites] J Urol. 2006 Feb;175(2):739-43 [16407042.001]
  • [Cites] Oncogene. 2003 Aug 14;22(34):5348-57 [12917636.001]
  • [Cites] FEBS Lett. 2003 Jul 10;546(2-3):374-8 [12832072.001]
  • [Cites] Nature. 1995 Jan 5;373(6509):78-81 [7800043.001]
  • [Cites] FEBS Lett. 2004 Aug 27;573(1-3):15-8 [15327968.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jan;6(1):44-55 [15688066.001]
  • [Cites] Genomics. 1996 Oct 15;37(2):183-6 [8921390.001]
  • [Cites] Mol Cell. 2004 May 21;14 (4):491-500 [15149598.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1127-38 [11948124.001]
  • [Cites] J Proteome Res. 2004 Nov-Dec;3(6):1191-200 [15595728.001]
  • [Cites] J Cell Biol. 2005 Dec 19;171(6):947-54 [16344309.001]
  • [Cites] J Biol Chem. 2002 Jan 25;277(4):2958-64 [11709553.001]
  • [Cites] Neoplasia. 2000 May-Jun;2(3):208-25 [10935507.001]
  • [Cites] Nature. 2003 Sep 11;425(6954):188-91 [12968183.001]
  • [Cites] Mutat Res. 2005 Sep 4;577(1-2):275-83 [15922366.001]
  • [Cites] J Biol Chem. 2005 Jun 24;280(25):23566-75 [15817450.001]
  • [Cites] Mol Cell. 2005 Sep 16;19(6):817-28 [16168376.001]
  • [Cites] J Biol Chem. 2005 Feb 18;280(7):5611-21 [15569683.001]
  • [Cites] J Biol Chem. 2001 Nov 2;276(44):40389-95 [11384992.001]
  • [Cites] Mol Cell. 2005 Apr 1;18(1):1-12 [15808504.001]
  • [Cites] Oncogene. 2005 Apr 18;24(17):2899-908 [15838523.001]
  • [Cites] Chem Res Toxicol. 2004 Dec;17 (12 ):1706-15 [15606148.001]
  • [Cites] Trends Biochem Sci. 2003 Jun;28(6):321-8 [12826404.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13225-30 [14578449.001]
  • [Cites] Exp Cell Res. 2002 Nov 1;280(2):212-21 [12413887.001]
  • [Cites] Mol Cell Biol. 2005 Aug;25(16):7021-32 [16055714.001]
  • [Cites] Expert Opin Ther Targets. 2005 Dec;9(6):1203-16 [16300471.001]
  • [Cites] J Cell Biol. 2003 Nov 10;163(3):477-87 [14597774.001]
  • [Cites] Mol Cell. 2006 Mar 17;21(6):837-48 [16543152.001]
  • [Cites] Nucleic Acids Res. 2000 Mar 1;28(5):1145-53 [10666456.001]
  • [Cites] Gene. 1997 May 6;190(2):287-96 [9197546.001]
  • [Cites] J Biol Chem. 2005 Feb 11;280(6):5004-12 [15561718.001]
  • [Cites] FEBS Lett. 2005 Jun 20;579(16):3369-75 [15922331.001]
  • [Cites] Oncogene. 2005 Apr 14;24(16):2677-83 [15735760.001]
  • [Cites] Mol Cell. 2005 Jul 1;19(1):123-33 [15989970.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2793-8 [15087395.001]
  • [Cites] Mol Cell Biol. 2006 Mar;26(5):1786-94 [16478998.001]
  • [Cites] Dev Biol. 2005 Dec 1;288(1):60-72 [16248995.001]
  • [Cites] Annu Rev Biochem. 2004;73:39-85 [15189136.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2872-7 [11867732.001]
  • [Cites] Nature. 2002 Sep 12;419(6903):135-41 [12226657.001]
  • [Cites] EMBO J. 2002 Mar 15;21(6):1456-64 [11889051.001]
  • [Cites] Dev Cell. 2005 Dec;9(6):769-79 [16326389.001]
  • [Cites] Cancer Cell. 2004 May;5(5):465-75 [15144954.001]
  • [Cites] Hum Mol Genet. 2005 May 15;14(10):1351-65 [15829507.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4046-51 [10759568.001]
  • [Cites] Mol Biol Cell. 2006 Apr;17 (4):1643-51 [16421255.001]
  • [Cites] Chembiochem. 2005 Oct;6(10 ):1735-43 [16142820.001]
  • [Cites] Cell. 2003 Nov 26;115(5):565-76 [14651848.001]
  • [Cites] J Biol Chem. 2005 Feb 11;280(6):4102-10 [15590687.001]
  • [Cites] Mol Cell. 2003 Apr;11(4):1043-54 [12718889.001]
  • [Cites] Exp Hematol. 2003 Jun;31(6):446-54 [12829019.001]
  • [Cites] Nature. 2005 Jul 21;436(7049):428-33 [15931174.001]
  • [Cites] J Biol Chem. 2004 Nov 26;279(48):50157-66 [15355988.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):4755-63 [11709548.001]
  • [Cites] Nucleic Acids Res. 2005 Jul 19;33(13):4023-34 [16030353.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):979-82 [15959518.001]
  • [Cites] FEBS Lett. 1997 Jan 20;401(2-3):109-12 [9013868.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Aug 17;286(2):322-7 [11500040.001]
  • [Cites] J Biol Chem. 2000 Jul 14;275(28):20963-6 [10806190.001]
  • [Cites] Genomics. 1996 Sep 1;36(2):271-9 [8812453.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2958-63 [8610150.001]
  • [Cites] EMBO J. 1999 Nov 15;18(22):6455-61 [10562557.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 29;32(2):598-610 [14752048.001]
  • [Cites] Cell Cycle. 2002 Jul-Aug;1(4):245-9 [12429940.001]
  • [Cites] Mol Cell. 2004 Feb 27;13(4):611-7 [14992729.001]
  • (PMID = 16758298.001).
  • [ISSN] 1567-2379
  • [Journal-full-title] Journal of molecular histology
  • [ISO-abbreviation] J. Mol. Histol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / BC / BC 045418; United States / NCI NIH HHS / CA / CA 102630
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Chromatin; 0 / Enzymes; 0 / SUMO-1 Protein; 0 / Saccharomyces cerevisiae Proteins; EC 2.3.2.23 / RAD6 protein, S cerevisiae; EC 2.3.2.23 / Ubiquitin-Conjugating Enzymes; EC 2.7.7.- / Rad51 Recombinase; EC 3.6.4.- / DNA Helicases; EC 6.3.2.- / ubiquitin-conjugating enzyme UBC9
  •  go-up   go-down


41. Karavolos S, Caplin M, Benjamin E, Crow J, Mould T: Primary mucinous carcinoid tumour of the ovary: a case report. Eur J Gynaecol Oncol; 2006;27(6):618-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mucinous carcinoid tumour of the ovary: a case report.
  • Primary ovarian carcinoid tumours of the ovary are rare and represent less than 0.1% of ovarian malignancy.
  • We report a case of primary ovarian mucinous carcinoid tumour, of the atypical category, in a 34-year-old nulliparous woman.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoid Tumor / surgery. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Leiomyoma / diagnosis. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17290597.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


42. Jin ZH, Josserand V, Razkin J, Garanger E, Boturyn D, Favrot MC, Dumy P, Coll JL: Noninvasive optical imaging of ovarian metastases using Cy5-labeled RAFT-c(-RGDfK-)4. Mol Imaging; 2006 Jul;5(3):188-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Noninvasive optical imaging of ovarian metastases using Cy5-labeled RAFT-c(-RGDfK-)4.
  • The aim of this study was to determine whether RAFT-c(-RGDfK-)4 combined with optical imaging could allow noninvasive detection of deep ovarian metastases.
  • Human ovarian adenocarcinoma IGROV1 cells expressing low levels of integrin alphaVbeta3 (the main receptor for the cRGD peptide) were used for in vitro and in vivo assays in combination with Cy5-labeled RAFT-c(-RGDfK-)4, cRGD, or RAFT-c(-RbetaADfK-)4.
  • [MeSH-major] Carbocyanines. Neoplasm Metastasis / radiography. Ovarian Neoplasms / radiography. Ovarian Neoplasms / secondary. Peptides, Cyclic

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16954034.001).
  • [ISSN] 1535-3508
  • [Journal-full-title] Molecular imaging
  • [ISO-abbreviation] Mol Imaging
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbocyanines; 0 / Carrier Proteins; 0 / Integrin alphaVbeta3; 0 / Peptides, Cyclic; 0 / Polymers; 0 / cyanine dye 5; 0 / cyclic arginine-glycine-aspartic acid peptide
  •  go-up   go-down


43. Kongkam P, LeBlanc JK: Diagnosis of recurrent rectal cancer deep into the vaginal wall by transvaginal endoscopic ultrasound-guided fine needle aspiration. Endoscopy; 2008 Oct;40(10):873-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of recurrent rectal cancer deep into the vaginal wall by transvaginal endoscopic ultrasound-guided fine needle aspiration.
  • Local recurrent rectal cancer may present with extraluminal lesions.
  • Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) is good for diagnosis of such an extraluminal lesion.
  • A 51-year-old Asian female was diagnosed with uT3N0M0 rectal adenocarcinoma 31 months ago.
  • Final cytology confirmed recurrent rectal adenocarcinoma.
  • Subsequent surgery also confirmed a 2.3 cm grade II adenocarcinoma.
  • The uterus and ovary specimen were negative for disease.
  • We herein report a successful role of transvaginal EUS-FNA for early detection of recurrent rectal cancer at the vaginal wall after abdominoperineal resection (APR).
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Endosonography. Rectal Neoplasms / pathology. Vaginal Neoplasms / diagnosis. Vaginal Neoplasms / secondary


44. Ali S, Cohen C, Little JV, Sequeira JH, Mosunjac MB, Siddiqui MT: The utility of SMAD4 as a diagnostic immunohistochemical marker for pancreatic adenocarcinoma, and its expression in other solid tumors. Diagn Cytopathol; 2007 Oct;35(10):644-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The utility of SMAD4 as a diagnostic immunohistochemical marker for pancreatic adenocarcinoma, and its expression in other solid tumors.
  • Pancreatic adenocarcinoma is a genetic disease showing somatic mutations of multiple genes, including SMAD4.
  • SMAD4 is a tumor suppressor gene that is inactivated in a sub-set of pancreatic adenocarcinoma, either by the intragenic mutation of one allele in combination with the loss of the other allele or by homozygous deletion of both alleles.
  • This study examines SMAD4 expression in fine-needle aspiration cell blocks from patients with pancreatic adenocarcinoma, as well as a variety of human cancers, in order to assess its viability as a tumor marker.
  • A total of 100 patients with pancreatic adenocarcinoma, with diagnostic material from fine-needle aspiration cell blocks were selected for this study.
  • Cancers studied included endometrium (n = 100), colon (n = 100), ovary (n = 100), lung (n = 100), breast (n = 100), and malignant melanoma (n = 100).
  • SMAD4 staining was nuclear and the results for tumor cell positivity for primary sites studied are as follows: Pancreas (80/100; 80%), endometrium (0/100; 0%), colon (0/100; 0%), ovary (3/100; 3%), lung (0/100; 0%), breast (2/100; 2%), and malignant melanoma (4/100; 4%).
  • This study suggests that SMAD4 is an important marker for confirming a diagnosis of pancreatic adenocarcinoma as a primary tumor, as well as when it presents as a metastatic tumor on small fine-needle aspirate samples.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / metabolism. Smad4 Protein / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17854080.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / SMAD4 protein, human; 0 / Smad4 Protein
  •  go-up   go-down


45. Medeiros F, Bell DA: Pseudoneoplastic lesions of the female genital tract. Arch Pathol Lab Med; 2010 Mar;134(3):393-403
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several of the more common pseudoneoplastic lesions are discussed in this article, including microglandular hyperplasia of the cervix mimicking well-differentiated endometrial adenocarcinoma, reactive epithelial changes in the fallopian tubes mimicking adenocarcinoma or carcinoma in situ, and pregnancy changes in the ovary including pregnancy luteoma and large solitary luteinized follicular cyst of pregnancy and puerperium that may mimic ovarian neoplasms.
  • Awareness of the features of such lesions will aid in their correct diagnosis and prevent overtreatment of benign processes.
  • [MeSH-major] Genital Diseases, Female / diagnosis. Granuloma, Plasma Cell / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Genital Neoplasms, Female / classification. Genital Neoplasms, Female / diagnosis. Humans. Pregnancy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20196667.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 76
  •  go-up   go-down


46. Yemelyanova AV, Vang R, Judson K, Wu LS, Ronnett BM: Distinction of primary and metastatic mucinous tumors involving the ovary: analysis of size and laterality data by primary site with reevaluation of an algorithm for tumor classification. Am J Surg Pathol; 2008 Jan;32(1):128-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinction of primary and metastatic mucinous tumors involving the ovary: analysis of size and laterality data by primary site with reevaluation of an algorithm for tumor classification.
  • Distinction of primary ovarian mucinous tumors from metastatic/secondary mucinous tumors involving the ovaries is often challenging, not only at the time of intraoperative assessment when requested for surgical management (staging decisions) but also for final pathologic diagnosis.
  • To assess the general utility of this algorithm for distinction of primary and secondary mucinous tumors in the ovary and address the occurrence of exceptions (large unilateral metastases), analysis of tumor size and laterality data was performed using 194 tumors (52 primary tumors and 142 metastases), with metastases subclassified by primary site [colorectum (46), appendix (28 low-grade tumors, 20 carcinomas), pancreaticobiliary tract (20), small intestine (3), stomach (5), and endocervix (20)].
  • The original algorithm correctly classified 84% of tumors overall, including 100% of primary ovarian tumors and 77% of all metastases (colorectal: 74%; appendiceal: 79% of low-grade tumors, 100% of carcinomas; pancreaticobiliary: 95%; small intestinal: 33%; gastric: 80%; endocervical: 55%).
  • By adjusting the size criterion to 12 cm, performance of the algorithm was both maintained for primary ovarian tumors and improved for metastases, with correct classification of 86% of tumors overall, including 100% of primary tumors and 80% of metastases.
  • Recognition that metastatic colorectal carcinomas represent the most common metastases and have a greater tendency to violate the algorithm should prompt lowering of the threshold for suggesting the possibility of metastatic colorectal carcinoma for tumors displaying any microscopic features suggestive of that diagnosis, even when a history of primary colorectal carcinoma is lacking.
  • Use of the algorithm is intended as an adjunct to the complete clinicopathologic evaluation that ideally should occur when problematic mucinous tumors in the ovary are encountered.
  • [MeSH-major] Adenocarcinoma, Mucinous / classification. Algorithms. Neoplasm Metastasis / pathology. Ovarian Neoplasms / classification

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18162780.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Nourbakhsh M, Golestani A, Zahrai M, Modarressi MH, Malekpour Z, Karami-Tehrani F: Androgens stimulate telomerase expression, activity and phosphorylation in ovarian adenocarcinoma cells. Mol Cell Endocrinol; 2010 Dec 15;330(1-2):10-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Androgens stimulate telomerase expression, activity and phosphorylation in ovarian adenocarcinoma cells.
  • Androgens have been implicated in increasing ovarian cancer risk.
  • Most ovarian cancer cells have high telomerase activity which is effective in inducing ovarian carcinogenesis.
  • The purpose of this study was to investigate the effects of testosterone and androstenedione on the viability of an ovarian adenocarcinoma cell line, the activity and expression of telomerase, and the phosphorylation status of its catalytic subunit in these cells.
  • Results showed that androgens significantly increased the viability of ovarian cancer cells and that these hormones induced the expression, activity and phosphorylation of telomerase.
  • These findings might have implications for understanding the role of androgens in ovarian carcinogenesis.
  • [MeSH-major] Adenocarcinoma / enzymology. Androgens / pharmacology. Gene Expression Regulation, Neoplastic / drug effects. Ovarian Neoplasms / enzymology. Telomerase / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • Hazardous Substances Data Bank. ANDROSTENEDIONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20673788.001).
  • [ISSN] 1872-8057
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Androgens; 0 / Protein Kinase Inhibitors; 0 / RNA, Messenger; 3XMK78S47O / Testosterone; 409J2J96VR / Androstenedione; EC 2.7.1.137 / Phosphatidylinositol 3-Kinase; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


48. Gregory-Bass RC, Olatinwo M, Xu W, Matthews R, Stiles JK, Thomas K, Liu D, Tsang B, Thompson WE: Prohibitin silencing reverses stabilization of mitochondrial integrity and chemoresistance in ovarian cancer cells by increasing their sensitivity to apoptosis. Int J Cancer; 2008 May 1;122(9):1923-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prohibitin silencing reverses stabilization of mitochondrial integrity and chemoresistance in ovarian cancer cells by increasing their sensitivity to apoptosis.
  • Current approaches to the treatment of ovarian cancer are limited because of the development of resistance to chemotherapy.
  • Our study was designed to determine the role of Phb1 in regulating cellular growth and apoptosis in ovarian cancer cells.
  • Our results showed that Phb1 content is differentially overexpressed in papillary serous ovarian carcinoma and endometrioid ovarian adenocarcinoma when compared to normal ovarian epithelium and was inversely related to Ki67 expression.
  • Immunofluorescence microscopy and Western analyses revealed that Phb1 is primarily associated with the mitochondria in ovarian cancer cells.
  • Over-expression of Phb1 by adenoviral Phb1 infection resulted in an increase in the percentage of ovarian cancer cells accumulating at G0/G1 phase of the cell cycle.
  • Treatment of ovarian cancer cells with staurosporine (STS) induced apoptosis in a time-dependent manner.
  • In contrast, silencing of Phb1 expression by adenoviral small interfering RNA (siRNA) sensitized ovarian cancer cells to STS-induce apoptosis.
  • Taken together, these results suggest that Phb1 induces block at G0/G1 phase of the cell cycle and promotes survival of cancer cells.
  • Furthermore, silencing of the Phb1 gene expression may prove to be a valuable therapeutic approach for chemoresistant ovarian cancer by increasing sensitivity of cancer cells to apoptosis.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [Cites] EMBO J. 2000 Jun 1;19(11):2444-51 [10835343.001]
  • [Cites] Exp Gerontol. 1996 Jan-Apr;31(1-2):245-52 [8706794.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1699-706 [11245486.001]
  • [Cites] Exp Cell Res. 2001 May 1;265(2):262-73 [11302691.001]
  • [Cites] Endocrinology. 2001 Sep;142(9):4076-85 [11517187.001]
  • [Cites] Mech Ageing Dev. 2002 Feb;123(4):287-95 [11744041.001]
  • [Cites] Oncogene. 2002 Jul 4;21(29):4539-48 [12085232.001]
  • [Cites] J Biol Chem. 2002 Nov 22;277(47):44870-6 [12244097.001]
  • [Cites] Exp Cell Res. 2003 Feb 15;283(2):135-45 [12581734.001]
  • [Cites] Endocrinology. 2003 Apr;144(4):1496-505 [12639934.001]
  • [Cites] Cell Death Differ. 2003 Aug;10(8):870-80 [12867994.001]
  • [Cites] J Biol Chem. 2003 Aug 22;278(34):32091-9 [12794069.001]
  • [Cites] Oncogene. 2004 Apr 15;23(17):2996-3004 [14968116.001]
  • [Cites] EMBO J. 2004 Jun 2;23(11):2293-303 [15141164.001]
  • [Cites] Biol Reprod. 2004 Jul;71(1):282-90 [15028627.001]
  • [Cites] J Reprod Fertil. 1997 Mar;109(2):337-48 [9155744.001]
  • [Cites] Mol Endocrinol. 1999 Aug;13(8):1364-72 [10446909.001]
  • [Cites] Anat Rec. 1999 Sep 1;256(1):40-8 [10456984.001]
  • [Cites] Mol Biol Cell. 2005 Jan;16(1):248-59 [15525670.001]
  • [Cites] Trends Mol Med. 2005 Apr;11(4):192-7 [15823758.001]
  • [Cites] Nat Cell Biol. 2005 Aug;7(8):837-43 [16041367.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6325-32 [16144937.001]
  • [Cites] Curr Cancer Drug Targets. 2006 May;6(3):207-27 [16712458.001]
  • [Cites] J Biol Chem. 2006 Nov 24;281(47):36401-10 [17008324.001]
  • [Cites] Endocrinology. 2007 Jan;148(1):206-17 [17038561.001]
  • [Cites] Oncogene. 2007 Mar 15;26(12):1757-68 [16964284.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):815-9 [17429401.001]
  • [Cites] Front Biosci. 2007;12:3628-39 [17485326.001]
  • [Cites] J Biol Chem. 2007 Jul 6;282(27):19426-41 [17493932.001]
  • [Cites] Reprod Biol Endocrinol. 2003 Oct 7;1:66 [14609433.001]
  • [Cites] Proteomics. 2004 Oct;4(10):3276-87 [15378696.001]
  • [Cites] Cell. 1986 Dec 5;47(5):767-76 [3779841.001]
  • [Cites] Trends Genet. 1993 Jan;9(1):22-6 [8434413.001]
  • [Cites] J Cell Physiol. 1993 Nov;157(2):289-95 [8227162.001]
  • [Cites] Cancer Lett. 1994 Aug 15;83(1-2):201-7 [8062216.001]
  • [Cites] J Biol Chem. 2000 Nov 24;275(47):37101-9 [10958795.001]
  • (PMID = 18183577.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / 1 C06 RR18386; United States / NCRR NIH HHS / RR / G12 RR003034; United States / NCRR NIH HHS / RR / C06 RR018386; United States / NICHD NIH HHS / HD / R01 HD057235; United States / FIC NIH HHS / TW / R21 TW006804-02S1; United States / NCRR NIH HHS / RR / RR03034; United States / NCATS NIH HHS / TR / UL1 TR000454; United States / FIC NIH HHS / TW / R21 TW006804-01; United States / NICHD NIH HHS / HD / U54 HD041749; United States / NICHD NIH HHS / HD / U54 HD041749-01; United States / NICHD NIH HHS / HD / U54 HD41749; United States / FIC NIH HHS / TW / R21 TW006804; United States / FIC NIH HHS / TW / R21 TW006804-02
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Ki-67 Antigen; 0 / RNA, Small Interfering; 0 / Recombinant Proteins; 0 / Repressor Proteins; 0 / prohibitin; EC 3.4.22.- / Caspase 3; H88EPA0A3N / Staurosporine
  • [Other-IDs] NLM/ NIHMS350695; NLM/ PMC3272361
  •  go-up   go-down


49. Hashiguchi Y, Tsuda H, Inoue T, Berkowitz RS, Mok SC: PTEN expression in clear cell adenocarcinoma of the ovary. Gynecol Oncol; 2006 Apr;101(1):71-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PTEN expression in clear cell adenocarcinoma of the ovary.
  • OBJECTIVES: In this study, we analyzed the PTEN expression in a large collection of clear cell adenocarcinomas of the ovary.
  • Cyclin D1 expression and loss of p27 expression were detected in 16/40 (40.0%) and 14/40 (35.0%) clear cell adenocarcinoma cases.
  • CONCLUSIONS: Loss of PTEN expression is relatively common and both cyclin D1 and p27 expressions are not related with PTEN inactivation in clear cell adenocarcinoma of the ovary.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Ovarian Neoplasms / metabolism. PTEN Phosphohydrolase / biosynthesis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16290000.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 136601-57-5 / Cyclin D1; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


50. Wang KL, Yang YC, Lai JC, Tsai TH, Lin CP, Wu YT, Chen YY, Wang SC, Chen YJ: Comparison in purity and antitumor effect of brand and generic paclitaxel against human ovarian cancer cells by an in vitro experimental model. Drug Dev Ind Pharm; 2010 Oct;36(10):1253-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison in purity and antitumor effect of brand and generic paclitaxel against human ovarian cancer cells by an in vitro experimental model.
  • By assessing the IC(50), generic paclitaxel also exhibited a greater inhibitory activity on clonogenicity of human ovarian adenocarcinoma SKOV-3 cells.
  • DISCUSSION AND CONCLUSION: The results suggest that generic paclitaxel may possess a greater cell death inducing capacity and clonogenicity inhibitory activity against ovarian cancer cells than the original brand Taxol of the same purity.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / chemistry. Antineoplastic Agents, Phytogenic / therapeutic use. Drugs, Generic / chemistry. Drugs, Generic / therapeutic use. Ovarian Neoplasms / drug therapy. Paclitaxel / chemistry. Paclitaxel / therapeutic use
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Apoptosis / drug effects. Cell Cycle / drug effects. Cell Line, Tumor. Cell Survival. Drug Screening Assays, Antitumor. Female. Humans. Mitosis / drug effects

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20818963.001).
  • [ISSN] 1520-5762
  • [Journal-full-title] Drug development and industrial pharmacy
  • [ISO-abbreviation] Drug Dev Ind Pharm
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Drugs, Generic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


51. Vang R, Gown AM, Farinola M, Barry TS, Wheeler DT, Yemelyanova A, Seidman JD, Judson K, Ronnett BM: p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas. Am J Surg Pathol; 2007 May;31(5):653-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas.
  • Distinction of primary ovarian epithelial tumors from metastatic adenocarcinomas is challenging for tumors exhibiting mucinous, endometrioid, or mixed endometrioid/mucinous differentiation.
  • Most endocervical adenocarcinomas exhibit mucinous and/or endometrioid differentiation; they infrequently metastasize to the ovaries but may simulate primary ovarian tumors [both atypical proliferative (borderline) and carcinoma].
  • The performance of this expression pattern for identifying metastatic endocervical adenocarcinomas in the ovaries among primary ovarian tumors and other metastatic adenocarcinomas having mucinous and/or endometrioid/endometrioidlike differentiation has not been evaluated.
  • Immunohistochemical expression of p16 was assessed in 195 tumors, including 98 primary ovarian tumors (51 mucinous, 47 endometrioid, and 4 mixed mucinous-endometrioid tumors), 93 metastatic adenocarcinomas of known primary sites (colorectum: 34, endocervix: 19, pancreaticobiliary tract: 17, appendix: 7, stomach: 5), 11 metastatic adenocarcinomas of unknown origin (7 established as noncervical), and 4 adenocarcinomas of uncertain (primary ovarian vs. metastatic) origin.
  • Mean and median expression values for HPV-positive endocervical adenocarcinomas (99%, 100%; range 90% to 100%) were substantially higher than those for primary ovarian mucinous (5%, 0%; range 0% to 70%) and endometrioid (20%, 10%; range 0% to 100%) tumors, HPV-unrelated endocervical adenocarcinomas (0%, 0%; range 0% to 60%), metastatic adenocarcinomas of unknown origin (11%, 0%; range 0% to 30%), and adenocarcinomas of uncertain (primary ovarian vs. metastatic) origin (40%, 35%; range 0% to 90%); only the 15 HPV-positive endocervical adenocarcinomas and 6 other tumors had values of 80% or greater.
  • Diffuse (>75% positive tumor cells) moderate to strong p16 expression is a sensitive (100%) and specific (97%) marker for identifying HPV-related endocervical adenocarcinomas metastatic to the ovary among the primary ovarian tumors and metastatic adenocarcinomas from other sites that are in the differential diagnosis of ovarian tumors having mucinous and/or endometrioid/endometrioidlike differentiation. p16 is useful as part of a panel of immunohistochemical markers for distinguishing primary ovarian tumors from metastases and, when diffusely positive, can suggest the cervix as a potential primary site for metastatic adenocarcinomas of unknown origin.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma, Mucinous / metabolism. Carcinoma, Endometrioid / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Ovarian Neoplasms / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. DNA, Viral / analysis. Diagnosis, Differential. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization. Papillomaviridae / genetics. Papillomavirus Infections. Polymerase Chain Reaction


52. Ang D, Ng KY, Tan HK, Chung AY, Yew BS, Lee VK: Ovarian carcinoma presenting with isolated contralateral inguinal lymph node metastasis: a case report. Ann Acad Med Singapore; 2007 Jun;36(6):427-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian carcinoma presenting with isolated contralateral inguinal lymph node metastasis: a case report.
  • INTRODUCTION: Ovarian carcinoma usually presents at an advanced stage with diffuse intraabdominal manifestations.
  • CLINICAL PICTURE: The only clinical abnormality was an enlarged right inguinal lymph node (3 x 2 cm), for which excision biopsy revealed metastatic adenocarcinoma.
  • A computed tomography (CT) scan showed an enlarged left ovarian lesion (9.0 x 6.4 cm).
  • Histology confirmed left ovarian adenocarcinoma, consistent with the earlier histology of the right inguinal lymph node.
  • Postoperatively, the patient received adjuvant chemotherapy for treatment of FIGO Stage IIIc ovarian carcinoma and is clinically disease free 13 months after surgery.
  • CONCLUSIONS: Ovarian cancer presenting with inguinal lymph node metastases is uncommon.
  • Ovarian cancer which manifests solely as a contralateral inguinal lymph node metastasis has not been previously reported.
  • This case illustrates a rare presentation of ovarian carcinoma, and underscores the need to consider ovarian carcinoma in the differential diagnosis of women with inguinal lymphadenopathy.
  • [MeSH-major] Adenocarcinoma / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17597969.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


53. Yadav S, van Vlerken LE, Little SR, Amiji MM: Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells. Cancer Chemother Pharmacol; 2009 Mar;63(4):711-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells.
  • Upon administration in multidrug resistant SKOV3(TR) human ovarian adenocarcinoma cells, siRNA-mediated MDR-1 gene silencing was evident at 100 nM dose.
  • [MeSH-major] Drug Resistance, Multiple. Gene Silencing. Nanoparticles. Ovarian Neoplasms / therapy. P-Glycoprotein / genetics. Paclitaxel / administration & dosage. Polyesters / administration & dosage

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18618115.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA119617
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / Antineoplastic Agents, Phytogenic; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 0 / Polyesters; 0 / RNA, Small Interfering; 0 / polyethylene oxide-polycaprolactone copolymer; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


54. Shield PW, Koivurinne K: The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions. Cytopathology; 2008 Aug;19(4):218-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To determine the value of calretinin and cytokeratin (CK) 5/6 in discriminating mesothelioma from adenocarcinoma in serous effusion specimens.
  • The adenocarcinomas included metastatic carcinomas from the breast (12), lung (19), stomach (3), colon (1), pancreas (2), ovary (6) endometrium (1) and 23 histologically confirmed metastases from unknown primary sites.
  • Only 3% (2/67) of adenocarcinomas were positive for calretinin, one being a lung adenocarcinoma and the other an adenocarcinoma of unknown primary site in an ascitic fluid.
  • Six (9%) adenocarcinomas were positive, including metastases from the lung (1), breast (1), ovary (2) and unknown primary site (2).
  • Four of the six adenocarcinoma cases positive for CK5/6 were in ascitic fluids.
  • Only one adenocarcinoma case, (which was from unknown primary site in an ascitic fluid sample), was positive for both markers.
  • The two markers make a useful addition to EMA and the panel of adenocarcinoma markers routinely applied to effusion specimens.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma / diagnosis. Keratin-5 / analysis. Keratin-6 / analysis. Mesothelioma / diagnosis. Neoplasms / diagnosis. S100 Calcium Binding Protein G / analysis
  • [MeSH-minor] Calbindin 2. Diagnosis, Differential. Humans. Pleural Effusion / pathology. Reproducibility of Results. Sensitivity and Specificity. Staining and Labeling

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17916095.001).
  • [ISSN] 1365-2303
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / Keratin-5; 0 / Keratin-6; 0 / S100 Calcium Binding Protein G
  •  go-up   go-down


55. Ganta S, Devalapally H, Amiji M: Curcumin enhances oral bioavailability and anti-tumor therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulation. J Pharm Sci; 2010 Nov;99(11):4630-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The results of this study suggest that combination of PTX and CUR, administered in nanoemulsions, could improve oral bioavailability and therapeutic efficacy in ovarian adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / pharmacokinetics. Antineoplastic Agents, Phytogenic / therapeutic use. Curcumin / pharmacology. Enzyme Inhibitors / pharmacology. Ovarian Neoplasms / drug therapy. Paclitaxel / pharmacokinetics. Paclitaxel / therapeutic use

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CURCUMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Wiley-Liss, Inc. and the American Pharmacists Association
  • (PMID = 20845461.001).
  • [ISSN] 1520-6017
  • [Journal-full-title] Journal of pharmaceutical sciences
  • [ISO-abbreviation] J Pharm Sci
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA119617
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Emulsions; 0 / Enzyme Inhibitors; 0 / P-Glycoprotein; EC 1.14.14.1 / Cytochrome P-450 CYP3A; IT942ZTH98 / Curcumin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


56. Veroni S, Terzopoulou K, Anagnostopoulou I, Vassilakaki T, Grammatoglou X, Rammou R: Extraovarian peritoneal serous papillary carcinoma: a case report. Acta Cytol; 2010 Sep-Oct;54(5 Suppl):879-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Extraovarian peritoneal serous papillary carcinoma (EPSPC) is a rare cancer closely related to ovarian carcinoma and characterized by abdominal carcinomatosis without an identifiable abdominal primary tumor.
  • Peritoneal carcinomatosis without involvement of the ovaries was found.
  • Paracentesis of the ascitic fluid resulted in a positive cytologic report not further suggestive of the malignancy origin, balancing between a mesothelioma and an adenocarcinoma.
  • The histologic and immunohistochemical study of peritoneal biopsy specimens resulted in the diagnosis of EPSPC.
  • CONCLUSION: The combination of cytology, histology, immunohistochemistry and clinical data is a reliable method for the preoperative diagnosis of EPSPC, allowing prompt chemotherapy as surgery may not be indicated in most cases.
  • [MeSH-major] Carcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / pathology. Ovary / pathology. Peritoneal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053561.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  •  go-up   go-down


57. Botana Rial M, Fernández-Villar A, González Piñeiro A, Leiro Fernández V: [Primary lung adenocarcinoma with ovarian metastasis: a rare presentation of bronchogenic carcinoma]. Arch Bronconeumol; 2009 Nov;45(11):571-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary lung adenocarcinoma with ovarian metastasis: a rare presentation of bronchogenic carcinoma].
  • [Transliterated title] Adenocarcinoma de origen pulmonar con enfermedad metástasica en ovario: una forma rara de presentación de carcinoma broncogénico.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Bronchogenic / secondary. Lung Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19467750.001).
  • [ISSN] 1579-2129
  • [Journal-full-title] Archivos de bronconeumología
  • [ISO-abbreviation] Arch. Bronconeumol.
  • [Language] spa
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  •  go-up   go-down


58. Jung SH, Jung SH, Seong H, Cho SH, Jeong KS, Shin BC: Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity. Int J Pharm; 2009 Dec 1;382(1-2):254-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vivo antitumor activity of DOX-loaded PCL was comparable to that of Doxil against human SKOV-3 ovarian adenocarcinoma xenograft rat model.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antibiotics, Antineoplastic / pharmacology. Doxorubicin / pharmacology. Drug Carriers. Ovarian Neoplasms / drug therapy. Polyethylene Glycols / chemistry

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19666094.001).
  • [ISSN] 1873-3476
  • [Journal-full-title] International journal of pharmaceutics
  • [ISO-abbreviation] Int J Pharm
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Drug Carriers; 0 / Liposomes; 30IQX730WE / Polyethylene Glycols; 80168379AG / Doxorubicin
  •  go-up   go-down


59. Ozbey C, Erdogan G, Pestereli HE, Simsek T, Karaveli S: Serous papillary adenocarcinoma and adult granulosa cell tumor in the same ovary. An unusual case. APMIS; 2005 Oct;113(10):713-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous papillary adenocarcinoma and adult granulosa cell tumor in the same ovary. An unusual case.
  • Surface epithelial-stromal cell tumors are the most common neoplasms of the ovary but occurrence of a serous adenocarcinoma and an adult granulosa cell tumor in the same ovary is an unusual incident.
  • In the present case report we describe this very uncommon occurrence in the ovary of a 50-year-old woman.
  • Microscopy revealed an adult granulosa cell tumor and a serous papillary adenocarcinoma in the left ovary.
  • Immunohistochemical staining with inhibin alpha and pancytokeratin confirmed the diagnosis.
  • [MeSH-major] Cystadenocarcinoma, Serous / pathology. Granulosa Cell Tumor / pathology. Ovarian Neoplasms / pathology. Ovary / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] APMIS. 2007 Jun;115(6):769-71 [17550386.001]
  • (PMID = 16309432.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / inhibin-alpha subunit; 57285-09-3 / Inhibins; 68238-35-7 / Keratins
  •  go-up   go-down


60. Handa U, Chhabra S, Mohan H: Aspiration cytology of extramammary tumours metastatic to the breast. Indian J Pathol Microbiol; 2007 Oct;50(4):855-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The metastatic tumors included, 2 cases of malignant melanoma (chest wall and left arm), 1 case each of haematolymphoid malignancy, adenocarcinoma of the ovary, and squamous cell carcinoma (left leg).
  • FNA diagnosis of metastasis to the breast is essential in order to avoid unnecessary mastectomy and to ensure appropriate chemotherapy and/or irradiation treatment.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Neoplasm Metastasis / diagnosis. Neoplasm Metastasis / pathology
  • [MeSH-minor] Adolescent. Adult. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18306588.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


61. Martínez-Cornelio A, Flores-López D, Ojeda RF, Quintero-Becerra J, Hernández-Toriz N: [Surgical experience with urachal carcinoma]. Cir Cir; 2009 Jan-Feb;77(1):33-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Experiencia quirúrgica en el adenocarcinoma de uraco.
  • Clinical files were reviewed of patients with diagnosis of bladder cancer and who were operated on with radical cystectomy with urinary substitution and extended partial cystectomy, selecting those patients with pathological report of urachal carcinoma.
  • RESULTS: Of the 306 patients operated on with radical surgery for bladder cancer, only five patients (1.6%) had a diagnosis of urachal carcinoma.
  • In one case, tumor of the right ovary was documented and the patient underwent exploratory laparotomy and extended partial cystectomy.
  • [MeSH-major] Adenocarcinoma / surgery. Urachus. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19344561.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


62. Shimizudani N, Senba S, Komiyama M, Hatao H, Ito M, Kioi K, Sudo A, Kishi K, Yagyu H, Oh-ishi S, Nakamura H, Matsuoka T: [A case of pseudo-meigs syndrome due to ovarian clear cell adenocarcinoma]. Nihon Kokyuki Gakkai Zasshi; 2005 Apr;43(4):236-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of pseudo-meigs syndrome due to ovarian clear cell adenocarcinoma].
  • Computed tomography (CT) of the abdomen showed a huge mass of the right ovary with a small amount of ascites, suggesting a diagnosis of Meigs syndrome.
  • The ovarian mass and the neighboring organs, including the uterus and the greater omentum, were surgically removed, and then both the bilateral pleural effusion and ascites disappeared after the surgery.
  • The histopathological examination revealed that the mass was clear cell adenocarcinoma of the ovary (stage IIc), indicating that the disease was pseudo-Meigs Syndrome.
  • This is the second report of pseudo-Meigs Syndrome caused by clear cell adenocarcinoma of the ovary in Japan.
  • [MeSH-major] Adenocarcinoma, Clear Cell / complications. Adenocarcinoma, Clear Cell / surgery. Meigs Syndrome / etiology. Ovarian Neoplasms / complications. Ovarian Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966371.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


63. Rouzi AA, Sahly NN, Sahly NF, Alahwal MS: Cisplatinum and docetaxel for ovarian cancer in pregnancy. Arch Gynecol Obstet; 2009 Nov;280(5):823-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cisplatinum and docetaxel for ovarian cancer in pregnancy.
  • BACKGROUND: There is limited data on chemotherapy for advanced ovarian cancer during pregnancy.
  • There are no published reports on the use of docetaxel for ovarian cancer in pregnancy.
  • CASE: A 32-year-old pregnant lady underwent laparatomy at 18-week gestation for ruptured ovarian cyst.
  • A diagnosis of stage IIIC, poorly differentiated papillary serous adenocarcinoma of the ovary was made.
  • CONCLUSION: This is the first report on the use of docetaxel during pregnancy for ovarian cancer.
  • [MeSH-major] Adenocarcinoma, Papillary / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy. Pregnancy Complications, Neoplastic / drug therapy


64. Salgado J, Gil C, Robles M, García-Foncillas J: A novel BRCA1 mutation in a Spanish patient with ovarian cancer. Breast Cancer Res Treat; 2009 Jan;113(1):71-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel BRCA1 mutation in a Spanish patient with ovarian cancer.
  • We report a novel germline 3536delT mutation in BRCA1 gene, detected in a 43-year-old woman with bilateral ovarian adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Genes, BRCA1. Germ-Line Mutation. Ovarian Neoplasms / genetics


65. Kanoh A, Seko A, Ideo H, Yoshida M, Nomoto M, Yonezawa S, Sakamoto M, Kannagi R, Yamashita K: Ectopic expression of N-acetylglucosamine 6-O-sulfotransferase 2 in chemotherapy-resistant ovarian adenocarcinomas. Glycoconj J; 2006 Jul;23(5-6):453-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ectopic expression of N-acetylglucosamine 6-O-sulfotransferase 2 in chemotherapy-resistant ovarian adenocarcinomas.
  • Mucinous and clear cell adenocarcinomas are the major histological types of ovarian epithelial cancer and are associated with a poor prognosis due to their resistance to chemotherapy.
  • A novel tumor marker specific for ovarian mucinous and clear cell adenocarcinomas would be helpful for overcoming these serious diseases.
  • We showed previously by enzymological characterization and RT-PCR that colonic mucinous adenocarcinoma tissues ectopically express GlcNAc6ST-2, a member of the carbohydrate 6-O-sulfotransferase family (Seko, A. et al. (2002) Glycobiology 12, 379-388).
  • Here, we prepared a GlcNAc6ST-2-specific polyclonal antibody for immunohistochemical analysis and found that GlcNAc6ST-2 is ectopically expressed by not only colonic mucinous adenocarcinomas but also ovarian mucinous, clear cell and papillary serous adenocarcinomas.
  • RT-PCR analysis confirmed that GlcNAc6ST-2 transcripts are expressed in ovarian mucinous adenocarcinomas but not in mucinous adenomas.
  • In addition, immunohistochemical analysis using sulfated glycan-specific monoclonal antibodies showed that ovarian adenocarcinoma cells express GlcNAc 6-O-sulfated glycans, including an L-selectin ligand and its related glycans.
  • These results indicate that GlcNAc6ST-2 would be a novel tumor antigen that is specifically expressed in ovarian mucinous, clear cell and papillary serous adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / enzymology. Drug Resistance, Neoplasm / physiology. Ovarian Neoplasms / enzymology. Sulfotransferases / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Biol Markers. 1998 Oct-Dec;13(4):179-87 [10228898.001]
  • [Cites] J Cell Biol. 1999 May 17;145(4):899-910 [10330415.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):193-8 [10188718.001]
  • [Cites] Science. 1990 Nov 23;250(4984):1130-2 [1701274.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Sep 24;263(2):543-9 [10491328.001]
  • [Cites] Am J Clin Pathol. 1991 Dec;96(6):711-6 [1720922.001]
  • [Cites] BMJ. 1996 Nov 30;313(7069):1355-8 [8956699.001]
  • [Cites] J Biol Chem. 2001 Dec 21;276(51):47747-50 [11585845.001]
  • [Cites] J Biol Chem. 1998 May 1;273(18):11225-33 [9556613.001]
  • [Cites] Gynecol Oncol. 1993 Jan;48(1):38-49 [8423020.001]
  • [Cites] Cell. 2001 Jun 29;105(7):957-69 [11439191.001]
  • [Cites] Cancer Res. 1999 May 1;59(9):2127-35 [10232599.001]
  • [Cites] Lancet. 1999 Apr 10;353(9160):1207-10 [10217079.001]
  • [Cites] Obstet Gynecol. 1993 Jul;82(1):143-7 [8515915.001]
  • [Cites] Cancer Res. 1993 Jan 15;53(2):354-61 [7678075.001]
  • [Cites] Oncol Res. 1999;11(5):233-41 [10608618.001]
  • [Cites] J Biol Chem. 1998 Aug 28;273(35):22577-83 [9712885.001]
  • [Cites] Immunity. 2001 Aug;15(2):237-47 [11520459.001]
  • [Cites] J Biol Chem. 2002 Feb 8;277(6):3979-84 [11726653.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1544-50 [9537262.001]
  • [Cites] Glycobiology. 2002 Jun;12(6):379-88 [12107080.001]
  • [Cites] Hum Mutat. 2003 Mar;21(3):285-91 [12619114.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1138-50 [1904477.001]
  • [Cites] Glycobiology. 2000 Sep;10(9):919-29 [10988253.001]
  • [Cites] Cancer Res. 1994 Jan 1;54(1):33-5 [8261457.001]
  • [Cites] Int J Oncol. 1999 Jun;14(6):1057-61 [10339657.001]
  • (PMID = 16897186.001).
  • [ISSN] 0282-0080
  • [Journal-full-title] Glycoconjugate journal
  • [ISO-abbreviation] Glycoconj. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; EC 2.8.2.- / Sulfotransferases; EC 2.8.2.- / carbohydrate sulfotransferases
  •  go-up   go-down


66. Tserkezoglou A, Kontou S, Hatjieleftheriou G, Nikolaidou ME, Plataniotis G, Apostolikas N, Magiakos G: Solitary parenchymal splenic recurrence of ovarian adenocarcinoma: a case report and review of the literature. Anticancer Res; 2005 Mar-Apr;25(2B):1471-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary parenchymal splenic recurrence of ovarian adenocarcinoma: a case report and review of the literature.
  • We report a rare case of solitary parenchymal splenic recurrence of epithelial ovarian cancer which developed 27 months after the initial treatment.
  • The patient, a 53-year-old woman, with a history of breast cancer, underwent total abdominal hysterectomy bilateral salpingo-ophorectomy (TAH & BSO), omentectomy and pelvic lymph node sampling for a serous carcinoma of the ovaries (stage IIIB).
  • Histopathological evaluation revealed metastatic parenchymal disease consistent with recurrent ovarian cancer.
  • Isolated parenchymal splenic lesions are very rare and may occur as a late recurrence in epithelial ovarian cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Cisplatin / therapeutic use. Splenic Neoplasms / secondary
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Hysterectomy. Middle Aged. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Splenectomy

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15865107.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  • [Number-of-references] 45
  •  go-up   go-down


67. Hopkins ML, Depetrillo AD, Le T, Fung MF: Pseudomyxoma peritonei: a case series and review of the literature. Int J Gynecol Cancer; 2005 Jan-Feb;15(1):32-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is a case series of patients with a diagnosis of PMP treated between January 1, 1995 and December 31, 2001.
  • The remaining patient underwent appendectomy, but it was not sufficiently sectioned for diagnosis.
  • Removal of mucinous tumors of the ovary should include appendectomy.
  • [MeSH-major] Adenocarcinoma / complications. Appendiceal Neoplasms / complications. Pseudomyxoma Peritonei / etiology. Pseudomyxoma Peritonei / surgery

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15670294.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 25
  •  go-up   go-down


68. Risse EK, Ouwerkerk-Noordam E, Meijer-Marres EM, Boon ME: Exploiting the residual of cervical thin layer brush samples through cytohistology in cases with invasive carcinoma with application of antibodies. Acta Cytol; 2010 Mar-Apr;54(2):175-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eight women had squamous cell carcinoma, 4 endocervical adenocarcinoma, 1 endometrial adenocarcinoma and 1 ovarian adenocarcinoma.
  • RESULTS: The morphologic details in the cancer nuclei in the paraffin sections were excellent, while in all cases the thin layer cytology slide contained thick epithelial fragments with blurred nuclei.
  • In 5 of the 6 adenocarcinomas, the glandular architecture diagnostic of adenocarcinoma was visible in the cytohistology, which was highlighted in the biomarker stainings, particularly so in the Ki-67 sections.
  • With the exception of endometrial adenocarcinoma, all p16(INK4a) stainings were positive, as they were in the ovarian adenocarcinoma case.
  • CONCLUSION: Cytohistology is an adjunct to routine cervical cytologic examination of thin layer samples, allowing an unequivocal and refined diagnosis.
  • [MeSH-major] Cytodiagnosis / methods. Immunohistochemistry / methods. Neoplasm, Residual / diagnosis. Uterine Cervical Neoplasms / diagnosis


69. Vang R, Gown AM, Barry TS, Wheeler DT, Ronnett BM: Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124 cases. Mod Pathol; 2006 Jan;19(1):97-105
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124 cases.
  • Estrogen (ER) and progesterone receptor (PR) expression in primary ovarian mucinous tumors and the utility of these markers for distinguishing metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors have not been extensively investigated.
  • Immunohistochemical studies were performed on 124 mucinous tumors, including 52 primary ovarian tumors (30 atypical proliferative (borderline) mucinous tumors of gastrointestinal type, 11 atypical proliferative (borderline) mucinous tumors of seromucinous (endocervical-like) type, and 11 invasive mucinous carcinomas of usual (gastrointestinal) type) and 72 metastatic mucinous carcinomas in the ovary (primary sites: colorectum (24), pancreas (13), endocervix (eight), stomach (four), gallbladder/bile duct (four), appendix (four), and unknown (15)).
  • All atypical proliferative mucinous tumors of gastrointestinal type, primary ovarian mucinous carcinomas, and metastatic mucinous carcinomas were negative for ER and PR with the exception of three metastatic endocervical adenocarcinomas which exhibited only weak expression of ER without PR.
  • Immunohistochemical assessment of hormone receptor expression is of no value in distinguishing the common types of primary ovarian mucinous tumors (atypical proliferative mucinous tumors of gastrointestinal type and mucinous carcinomas of usual type) from the vast majority of mucinous carcinomas metastatic to the ovary.
  • The above observations on hormone receptor expression in primary ovarian mucinous tumors support the concept that atypical proliferative (borderline) mucinous tumors of gastrointestinal and seromucinous (endocervical-like) types are distinctive tumors.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Ovarian Neoplasms / secondary. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis
  • [MeSH-minor] Appendiceal Neoplasms / metabolism. Appendiceal Neoplasms / pathology. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Diagnosis, Differential. Female. Gallbladder Neoplasms / metabolism. Gallbladder Neoplasms / pathology. Humans. Immunohistochemistry. Neoplasms, Unknown Primary / metabolism. Neoplasms, Unknown Primary / pathology. Ovary / chemistry. Ovary / pathology. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16294196.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


70. Jung HJ, Lee HY, Kim BW, Jung SM, Kim HG, Ji JS, Choi H, Lee BI: Gastric Metastasis from Ovarian Adenocarcinoma Presenting as a Submucosal Tumor without Ulceration. Gut Liver; 2009 Sep;3(3):211-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric Metastasis from Ovarian Adenocarcinoma Presenting as a Submucosal Tumor without Ulceration.
  • Metastatic gastric cancer is extremely rare and gastric metastasis from ovarian adenocarcinoma has rarely been reported.
  • We report a case of 49-year-old woman in which gastric metastasis from ovarian adenocarcinoma presented as a submucosal tumor without ulceration on endoscopic examination.
  • It was confirmed histopathologically as metastatic ovarian adenocarcinoma after endoscopic submucosal dissection (ESD) with enucleation.
  • Submucosal tumor of the stomach in patients with ovarian carcinoma should not be overlooked and ESD with enucleation may be a viable option when EUS with fine needle aspiration is not available.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endoscopy. 1996 Feb;28(2):249-53 [8739742.001]
  • [Cites] Gynecol Oncol. 1994 Oct;55(1):152-5 [7959258.001]
  • [Cites] Radiol Clin North Am. 1993 Nov;31(6):1359-73 [8210355.001]
  • [Cites] Am J Gastroenterol. 1992 Oct;87(10):1418-23 [1415098.001]
  • [Cites] Endoscopy. 2001 Jun;33(6):507-10 [11437044.001]
  • [Cites] Cancer. 1990 Apr 1;65(7):1596-600 [2311070.001]
  • [Cites] J Gastroenterol. 2004 Aug;39(8):747-53 [15338368.001]
  • [Cites] J Ultrasound Med. 2004 Sep;23(9):1141-50 [15328428.001]
  • [Cites] Cancer. 1987 Oct 1;60(7):1561-6 [3621129.001]
  • (PMID = 20431748.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2852710
  • [Keywords] NOTNLM ; Gastric metastasis / Ovarian adenocarcinoma / Submucosal tumor
  •  go-up   go-down


71. Santillan A, Bristow RE: Paraneoplastic cerebellar degeneration in a woman with ovarian cancer. Nat Clin Pract Oncol; 2006 Feb;3(2):108-12; quiz 1 p following 112
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraneoplastic cerebellar degeneration in a woman with ovarian cancer.
  • During her initial admission, the patient improved to some degree and was discharged with a possible diagnosis of viral meningitis.
  • DIAGNOSIS: Stage IIIC endometrioid adenocarcinoma of the ovary with paraneoplastic cerebellar degeneration.
  • [MeSH-major] Carcinoma, Endometrioid / diagnosis. Ovarian Neoplasms / diagnosis. Paraneoplastic Cerebellar Degeneration / diagnosis


72. McCluggage WG, Young RH: Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors. Semin Diagn Pathol; 2005 Feb;22(1):3-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors.
  • Aspects of immunohistochemistry (IHC), which are useful in the diagnosis of ovarian tumors (mostly neoplasms but also a few tumor-like lesions), are discussed.
  • The well-known staining of the latter neoplasm for S-100 protein and HMB-45 may be very helpful in evaluating melanomas with follicular or other unusual patterns, a challenging aspect of ovarian tumor interpretation.
  • IHC for neuroendocrine markers may assist in the diagnosis of primary and metastatic carcinoid tumor.
  • The broad differential diagnosis of glandular neoplasms with an endometrioid-pseudoendometrioid morphology, or mucinous cell type, has been the subject of much exploration in recent years, particularly the distinction between primary and metastatic neoplasms.
  • The rare differential of metastatic cervical adenocarcinoma versus primary ovarian mucinous or endometrioid carcinoma may be aided by strong p16 staining of the former.
  • Staining for alpha-fetoprotein may aid in confirming the diagnosis of endometrioid-like (and hepatoid) variants of yolk sac tumor.
  • Ependymoma of the ovary may also have an endometrioid-like glandular pattern, but positive stains for glial fibrillary acidic protein contrast with the negative results in others neoplasms with a similar pattern.
  • As in tumor pathology in general, various markers may be crucial in the diagnosis of small round cell tumors of the ovary, and familiar markers of epithelial, lymphoid, leukemic, and melanocytic neoplasms may assist in the analysis of high grade tumors with a poorly differentiated carcinoma, lymphoma-granulocytic sarcoma, malignant melanoma differential.
  • The evaluation of ovarian cystic lesions may be aided by thyroglobulin or TTF 1 (cystic struma), glial fibrillary acid protein (ependymal cysts), and inhibin-calretinin (follicle cysts and unilocular granulosa cell tumors).
  • [MeSH-major] Immunohistochemistry. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Neoplasm Metastasis. Ovarian Cysts / diagnosis. Ovarian Follicle / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16512597.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 115
  •  go-up   go-down


73. Turunen M, Talvensaari-Mattila A, Soini Y, Santala M: Claudin-5 overexpression correlates with aggressive behavior in serous ovarian adenocarcinoma. Anticancer Res; 2009 Dec;29(12):5185-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Claudin-5 overexpression correlates with aggressive behavior in serous ovarian adenocarcinoma.
  • The expression of claudin-5 and its correlation to ovarian cancer behavior was investigasted.
  • MATERIALS AND METHODS: A total of 85 serous ovarian cancer tissue samples were analyzed using immunohistochemical staining.
  • RESULTS: An association between claudin-5 expression and cancer grade (p=0.016) and advanced stage (p=0.022), strongest claudin-5 expression was found in advanced stage and high-grade carcinomas.
  • An association between claudin-5 expression and cancer-specific (p=0.032) and overall survival (p=0.026) was also found.
  • CONCLUSION: Increased claudin-5 expression is associated with aggressive behavior in serous ovarian adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Papillary / metabolism. Biomarkers, Tumor / metabolism. Cystadenocarcinoma, Serous / metabolism. Membrane Proteins / metabolism. Ovarian Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20044634.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CLDN5 protein, human; 0 / Claudin-5; 0 / Membrane Proteins
  •  go-up   go-down


74. Inan S, Vatansever S, Celik-Ozenci C, Sanci M, Dicle N, Demir R: Immunolocalizations of VEGF, its receptors flt-1, KDR and TGF-beta's in epithelial ovarian tumors. Histol Histopathol; 2006 10;21(10):1055-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunolocalizations of VEGF, its receptors flt-1, KDR and TGF-beta's in epithelial ovarian tumors.
  • In this study, we aimed to evaluate the immunolocalizations of vascular endothelial growth factor (VEGF), its receptors flt-1, KDR/flk-1, and transforming growth factor-beta's (TGF-beta) in epithelial ovarian tumors, utilizing indirect immunohistochemistry to understand the role of the angiogenic events in ovarian neoplasia.
  • METHODS: Tissue blocks from 40 patients who had ovarian pathology (borderline serous-mucinous tumor and malignant serous-mucinous adenocarcinoma of the ovary) were included in this study.
  • RESULTS: Positive VEGF immunoreactivity was concentrated in the epithelial and stromal parts of all the ovarian samples and the endothelial cells in the stroma were also stained.
  • Increased immunoreactivity of VEGF was observed in malignant ovarian adenocarcinomas compared to the borderline tumors of the ovary.
  • Immunoreactivities of VEGF and its receptors were coexpressed in tumor cells of the ovarian carcinoma.
  • While immunoreactivities of TGF-beta1 and TGF-beta2 were both overexpressed in malignant ovarian carcinomas, immunoreactivity of TGF-beta3 was still mild.
  • CONCLUSION: Our results suggest that overexpression of VEGF, its receptors flt-1, KDR/flk-1 and TGF-beta interaction may play an important role in the ovarian cancer biology, with potential effects on tumor growth and angiogenesis.
  • New therapeutic strategies using VEGF and TGF-beta antagonists could obtain an additional approach to the treatment ovarian carcinoma by inhibiting angiogenesis.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Immunohistochemistry / methods. Neovascularization, Pathologic. Ovarian Neoplasms / pathology. Ovary / pathology. Transforming Growth Factor beta / metabolism. Vascular Endothelial Growth Factor A / metabolism. Vascular Endothelial Growth Factor Receptor-1 / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16835828.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Transforming Growth Factor beta; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / FLT1 protein, human; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


75. Huang SF, Zhang YN: [Diagnosis of mucinous borderline tumor of ovary]. Zhonghua Bing Li Xue Za Zhi; 2008 Apr;37(4):223-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis of mucinous borderline tumor of ovary].
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Cystadenocarcinoma, Mucinous / diagnosis. Ovarian Neoplasms / pathology. Ovary / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18844029.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Lectures
  • [Publication-country] China
  •  go-up   go-down


76. Leroy-Dudal J, Heyman L, Gauduchon P, Carreiras F: Adhesion of human ovarian adenocarcinoma IGROV1 cells to endothelial cells is partly mediated by the alphav integrins-vitronectin adhesive system and induces an alteration of endothelial integrity. Cell Biol Int; 2005 Jun;29(6):482-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adhesion of human ovarian adenocarcinoma IGROV1 cells to endothelial cells is partly mediated by the alphav integrins-vitronectin adhesive system and induces an alteration of endothelial integrity.
  • Several lines of evidence suggest that vascularization plays an important role in the growth, local expansion and dissemination of ovarian epithelial tumours.
  • However, the interaction of ovarian carcinoma cells with the endothelium remains poorly understood.
  • To investigate adhesive events underlying this process, we used an in vitro model of cocultures between the IGROV1 human ovarian adenocarcinoma cell line and human umbilical vein endothelial cells (HUVECs).
  • Considering the ability of ovarian carcinoma to disseminate by a haematogenous way, these in vitro events could mimic a preliminary step for carcinoma cells crossing the endothelial barrier to extravasate.
  • [MeSH-major] Endothelial Cells / cytology. Endothelial Cells / metabolism. Integrin alphaV / metabolism. Ovarian Neoplasms / metabolism. Vitronectin / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15914035.001).
  • [ISSN] 1065-6995
  • [Journal-full-title] Cell biology international
  • [ISO-abbreviation] Cell Biol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Integrin alphaV; 0 / Vitronectin; 0 / von Willebrand Factor
  •  go-up   go-down


77. Dasanu CA, Herzog TJ: Clear cell adenocarcinoma of the ovary associated with in utero diethylstilbestrol exposure: case report and clinical overview. Medscape J Med; 2009;11(1):6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell adenocarcinoma of the ovary associated with in utero diethylstilbestrol exposure: case report and clinical overview.
  • BACKGROUND: Clear cell adenocarcinoma of the vagina and cervix were previously shown to be tumors occurring in female offspring exposed prenatally to diethylstilbestrol.
  • This report describes the first clinical case of clear cell adenocarcinoma of the ovary linked to early diethylstilbestrol exposure in utero.
  • She underwent surgery and staging that revealed clear cell adenocarcinoma confined to the left ovary.
  • CONCLUSION: Our case is consistent with clear cell adenocarcinoma, probably related to diethylstilbestrol exposure in utero.
  • [MeSH-major] Adenocarcinoma, Clear Cell / chemically induced. Diethylstilbestrol / adverse effects. Ovarian Neoplasms / chemically induced. Prenatal Exposure Delayed Effects / chemically induced

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Causes Control. 2001 Nov;12(9):837-45 [11714112.001]
  • [Cites] Cancer. 1980 Apr 1;45(7):1615-24 [7370920.001]
  • [Cites] Biol Reprod. 1983 Apr;28(3):735-44 [6850046.001]
  • [Cites] Int J Gynecol Pathol. 1989;8(2):85-96 [2469661.001]
  • [Cites] Epidemiology. 2008 Mar;19(2):251-7 [18223485.001]
  • [Cites] Semin Diagn Pathol. 1997 Nov;14(4):233-9 [9383823.001]
  • [Cites] Obstet Gynecol. 2005 Jan;105(1):167-73 [15625159.001]
  • [Cites] Int J Cancer. 2007 Jul 15;121(2):356-60 [17390375.001]
  • [Cites] Semin Surg Oncol. 1990;6(6):343-6 [2263810.001]
  • (PMID = 19295927.001).
  • [ISSN] 1934-1997
  • [Journal-full-title] Medscape journal of medicine
  • [ISO-abbreviation] Medscape J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 731DCA35BT / Diethylstilbestrol
  • [Other-IDs] NLM/ PMC2654676
  •  go-up   go-down


78. Zhu W, Michael CW: WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions. Diagn Cytopathol; 2007 Jun;35(6):370-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions.
  • The distinction between metastatic adenocarcinomas of lung (LAC), breast (BAC), and ovary (OAC) in serous effusions can be very difficult since they all can present as tight cell clusters.
  • The aim of this study is to evaluate the usefulness of WT1, monoclonal CEA (mCEA), TTF1, and CA125 antibodies in the differential diagnosis of metastatic adenocarcinoma from the lung, breast and ovary in serous effusions.
  • Our results demonstrate that the WT1 stain is specific for metastatic carcinoma of ovarian primary, showing a high sensitivity.
  • A positive TTF1 staining supports the diagnosis of metastatic carcinoma originating from lung rather than breast, while a negative TTF1 favors the diagnosis of a breast primary.
  • Immunohistochemical studies with WT1, TTF1, and mCEA antibodies are useful in the differential diagnosis of metastatic adenocarcinomas of lung, breast, and ovary.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antibodies, Monoclonal. CA-125 Antigen / immunology. Carcinoembryonic Antigen / immunology. Nuclear Proteins / immunology. Pleural Effusion, Malignant / diagnosis. Transcription Factors / immunology. WT1 Proteins / immunology
  • [MeSH-minor] Breast Neoplasms / diagnosis. Diagnosis, Differential. Female. Humans. Lung Neoplasms / diagnosis. Ovarian Neoplasms / diagnosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17497661.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / CA-125 Antigen; 0 / Carcinoembryonic Antigen; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / WT1 Proteins; 0 / thyroid nuclear factor 1
  •  go-up   go-down


79. Prat J: Ovarian carcinomas, including secondary tumors: diagnostically challenging areas. Mod Pathol; 2005 Feb;18 Suppl 2:S99-111
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian carcinomas, including secondary tumors: diagnostically challenging areas.
  • The differential diagnosis of ovarian carcinomas, including secondary tumors, remains a challenging task.
  • Mucinous carcinomas of the ovary are rare and can be easily confused with metastatic mucinous carcinomas that may present clinically as a primary ovarian tumor.
  • International Federation of Gynecology and Obstetrics (FIGO) stage is the single most important prognostic factor, and stage I carcinomas have an excellent prognosis; FIGO stage is largely related to the histologic features of the ovarian tumors.
  • Metastatic colon cancer is frequent and often simulates ovarian endometrioid adenocarcinoma.
  • Although immunostains for cytokeratins 7 and 20 can be helpful in the differential diagnosis, they should always be interpreted in the light of all clinical information.
  • Endometrioid carcinoma of the ovary is associated in 15-20% of the cases with carcinoma of the endometrium.
  • Krukenberg tumors are metastatic adenocarcinomas traditionally perceived as composed of mucin-filled signet-ring cells associated with a striking proliferation of the ovarian stroma but many variations on this pattern occur.
  • [MeSH-major] Ovarian Neoplasms / pathology
  • [MeSH-minor] Base Sequence. Colonic Neoplasms / pathology. Cytoskeletal Proteins / genetics. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Intermediate Filament Proteins / analysis. Keratin-20. Keratin-7. Keratins / analysis. Mutation. Prognosis. Trans-Activators / genetics. beta Catenin. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15492758.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / Cytoskeletal Proteins; 0 / Intermediate Filament Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / Trans-Activators; 0 / beta Catenin; 68238-35-7 / Keratins; EC 3.6.5.2 / ras Proteins
  • [Number-of-references] 63
  •  go-up   go-down


80. Kobayashi H: Ovarian cancer in endometriosis: epidemiology, natural history, and clinical diagnosis. Int J Clin Oncol; 2009 Oct;14(5):378-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian cancer in endometriosis: epidemiology, natural history, and clinical diagnosis.
  • We review whether endometriosis-associated ovarian cancer is a specific entity compared with ovarian cancer not associated with endometriosis, with respect to epidemiology, natural history, and clinical diagnosis; we present a review of the English-language literature for ovarian cancer in endometriosis with respect to these three features.
  • A recent prospective study in Japan directly showed that, during a follow-up of up to 17 years of an ovarian endometrioma cohort (n = 6398), 46 incident ovarian cancers were identified, showing that the ovarian cancer risk was significantly elevated in patients with ovarian endometrioma (standardized incidence ratio [SIR], 8.95; 95% confidence interval [CI], 4.12 to 15.3).
  • Advancing age (>40 years) and the size of the endometriomas (>9 cm) were independent predictors of the development of ovarian cancer among the women with ovarian endometrioma.
  • Although some endometriosis lesions may predispose to clear cell carcinoma (CCC) and endometrioid adenocarcinoma (EAC) of the ovary, both of these cancers differ from the other histological types with respect to their clinical characteristics and carcinogenesis.
  • In patients with endometriosis-associated ovarian cancer, benign-appearing ovarian masses are typically present several years before the diagnosis of the cancer.
  • A slightly elevated carbohydrate antigen [CA] 125 level is also typically present many years before the diagnosis in these patients.
  • However, serous-type ovarian cancer may exhibit a rapid progression possibly through de-novo carcinogenesis.
  • Ovarian endometrioma could be viewed as a neoplastic process, particularly in perimenopausal women.
  • Understanding the mechanisms of the development of endometriosis and elucidating its pathogenesis and pathophysiology are intrinsic to the prevention of endometriosis-associated ovarian cancer and the search for effective therapies.
  • [MeSH-major] Cell Transformation, Neoplastic. Endometriosis / diagnosis. Endometriosis / epidemiology. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / epidemiology. Precancerous Conditions / diagnosis. Precancerous Conditions / epidemiology

  • Genetic Alliance. consumer health - Endometriosis.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Cancer. 2005 Jan-Feb;15(1):37-44 [15670295.001]
  • [Cites] Gynecol Oncol. 2003 Mar;88(3):309-17 [12648580.001]
  • [Cites] Lancet Oncol. 2009 Apr;10 (4):327-40 [19282241.001]
  • [Cites] J Obstet Gynaecol Res. 2008 Oct;34(5):872-7 [18834345.001]
  • [Cites] Int J Gynecol Cancer. 2007 Jan-Feb;17(1):37-43 [17291229.001]
  • [Cites] Gynecol Oncol. 2000 Dec;79(3):466-70 [11104621.001]
  • [Cites] Int J Gynecol Pathol. 2008 Apr;27(2):151-60 [18317228.001]
  • [Cites] BMJ. 1993 Apr 17;306(6884):1030-4 [8490497.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):32-40 [18172249.001]
  • [Cites] Gynecol Oncol. 1999 Mar;72(3):342-6 [10053105.001]
  • [Cites] Int J Gynecol Cancer. 2003 Jul-Aug;13(4):466-71 [12911723.001]
  • [Cites] BMJ. 1996 Nov 30;313(7069):1355-8 [8956699.001]
  • [Cites] Cancer. 1995 Nov 15;76(10 Suppl):2086-91 [8635005.001]
  • [Cites] Gynecol Obstet Invest. 2000;50 Suppl 1:11-7 [11093056.001]
  • [Cites] Med J Aust. 2003 Jun 16;178(12 ):655-6 [12797860.001]
  • [Cites] Ann Acad Med Singapore. 1998 Sep;27(5):676-82 [9919339.001]
  • [Cites] Curr Opin Obstet Gynecol. 2000 Feb;12 (1):39-42 [10752515.001]
  • [Cites] Br J Cancer. 1999 Oct;81(3):559-63 [10507786.001]
  • [Cites] Int J Gynaecol Obstet. 2001 Jul;74(1):45-50 [11430940.001]
  • [Cites] Gynecol Oncol. 2003 Oct;91(1):15-31 [14529658.001]
  • [Cites] Int J Gynecol Cancer. 2008 May-Jun;18(3):414-20 [17645503.001]
  • [Cites] Semin Reprod Med. 2003 May;21(2):209-22 [12917790.001]
  • [Cites] Fertil Steril. 2004 Aug;82(2):405-14 [15302291.001]
  • [Cites] Lancet. 1999 Apr 10;353(9160):1207-10 [10217079.001]
  • [Cites] Lancet. 1988 Feb 6;1(8580):268-71 [2893084.001]
  • [Cites] Am J Obstet Gynecol. 1997 Mar;176(3):572-9 [9077609.001]
  • [Cites] Br J Cancer. 1999 Jul;80(10 ):1644-7 [10408412.001]
  • [Cites] Acta Obstet Gynecol Scand. 2004 Apr;83(4):395-400 [15005789.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1612-8 [11920519.001]
  • [Cites] Gynecol Obstet Invest. 2000;50 Suppl 1:18-25 [11093057.001]
  • [Cites] Semin Oncol. 1998 Jun;25(3):255-64 [9633839.001]
  • [Cites] Int J Gynaecol Obstet. 2007 Nov;99(2):95-9 [17643440.001]
  • [Cites] Oncol Rep. 2009 Aug;22(2):233-40 [19578761.001]
  • [Cites] Int J Gynaecol Obstet. 1997 Dec;59(3):245-50 [9486515.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1996 Apr;65(2):221-5 [8730628.001]
  • [Cites] Obstet Gynecol Clin North Am. 2001 Dec;28(4):637-51, vii [11766142.001]
  • [Cites] Am J Obstet Gynecol. 2003 Jul;189(1):280-94 [12861175.001]
  • [Cites] Semin Oncol. 1998 Jun;25(3):315-25 [9633843.001]
  • [Cites] Clin J Oncol Nurs. 2003 Jan-Feb;7(1):41-7 [12629933.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2008 Jun;138(2):187-93 [18162283.001]
  • [Cites] Am J Epidemiol. 2002 Feb 1;155(3):217-24 [11821246.001]
  • (PMID = 19856043.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Japan
  • [Number-of-references] 41
  •  go-up   go-down


81. Vrabie CD, Petrescu A, Waller M, Dina I: Clinical factors and biomarkers in ovarian tumors development. Rom J Morphol Embryol; 2008;49(3):327-38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical factors and biomarkers in ovarian tumors development.
  • Ovarian cancer is a disease difficult to detect in early stages due to nonspecific symptoms and has a rapid progression with frequent relapses after radical surgical procedure.
  • For these reasons, ovarian cancer generally represents the fourth cause of death through cancer in females, while in our country it is surpassed only by cervix cancer.
  • Therefore, the diagnosis is delayed, when the metastases are already present and the prognosis is poor.
  • While the etiology of the ovarian cancer is less understood, the histopathological studies and experiments regarding ovarian cancer development suggest that the majority of the tumors refined to the surface epithelium, a cuboidal layer that lays the ovary.
  • It is still unclear if the molecular changes in this layer generate a neoplastic precursor that can be used for establishing an early diagnosis.
  • Our study reveals that a high percent (68.33%) of females had a correct diagnosis at admission, only five patients (8.33%) being diagnosed with other diseases.
  • More than 75% were serous tumors, 20% mucinous carcinoma and 5% borderline ovarian tumors.
  • The analysis of hormone receptors showed estrogen receptors in 32 cases (71.1%) of serous ovarian adenocarcinoma, in seven cases (58.33%) of mucinous adenocarcinoma, all three cases (100%) of borderline tumors and in four cases (21.05%) of the 19 with peritoneal implants.
  • This study outlines that an immunohistochemical analysis of certain antibodies cannot offer useful data regarding the prognosis or the screening for ovarian cancer.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma / etiology. Carcinoma / pathology. Ovarian Neoplasms / etiology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18758637.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


82. Pothacharoen P, Siriaunkgul S, Ong-Chai S, Supabandhu J, Kumja P, Wanaphirak C, Sugahara K, Hardingham T, Kongtawelert P: Raised serum chondroitin sulfate epitope level in ovarian epithelial cancer. J Biochem; 2006 Oct;140(4):517-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Raised serum chondroitin sulfate epitope level in ovarian epithelial cancer.
  • OBJECTIVE: To determine the value of serum chondroitin sulfate epitope WF6 and hyaluronan (HA) levels as a biomarker for early detection of ovarian epithelial cancer and other gynecological disorders.
  • METHOD: Serum WF6 CS epitope and HA were measured in 91 patients with ovarian epithelial cancer, 39 patients with non-cancer gynecological disorders and 30 healthy women.
  • RESULTS: The serum concentration of CS (WF6) epitope was highly increased in epithelial types of ovarian cancer and at all stages of development (p < 0.005).
  • Serum HA in ovarian cancer patients was significantly higher than normal controls (p < 0.05).
  • CONCLUSION: These results reflect changes in ECM metabolism in progressive ovarian cancer, which cause an increase in serum CS epitopes and HA.
  • Therefore, serum CS epitopes may provide useful biomarkers for cancers and other disorders of the ovary.
  • Measurement of serum HA provided complementary information, which may be useful as a discriminator between benign ovarian disorders and malignant ovarian diseases.
  • [MeSH-major] Chondroitin Sulfates / blood. Hyaluronic Acid / blood. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Clear Cell / immunology. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / immunology. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / diagnosis. Adenocarcinoma, Papillary / immunology. Adenocarcinoma, Papillary / pathology. Adult. Aged. Antibodies, Monoclonal. Biomarkers, Tumor / blood. Carcinoma, Endometrioid / diagnosis. Carcinoma, Endometrioid / immunology. Carcinoma, Endometrioid / pathology. Cells, Cultured. Cross-Sectional Studies. Epitopes. Female. Humans. Hybridomas. Middle Aged

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16936295.001).
  • [ISSN] 0021-924X
  • [Journal-full-title] Journal of biochemistry
  • [ISO-abbreviation] J. Biochem.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Epitopes; 9004-61-9 / Hyaluronic Acid; 9007-28-7 / Chondroitin Sulfates
  •  go-up   go-down


83. Vrdoljak-Mozetic D, Stanković T, Krasević M, Versa-Ostojić D, Stemberger-Papić S, Rupcić S: Intraoperative cytology of clear cell carcinoma of the ovary. Cytopathology; 2006 Dec;17(6):390-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative cytology of clear cell carcinoma of the ovary.
  • OBJECTIVE: To describe the cytomorphology of clear cell carcinoma (CCC) of the ovary in intraoperative samples of peritoneal fluid, imprint and scraping samples of the tumour tissue.
  • CONCLUSION: Using cytological analysis of imprint and scraping samples of ovarian tumours it is possible to make a precise intraoperative cytological diagnosis in most cases of CCC of the ovary.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17168923.001).
  • [ISSN] 0956-5507
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


84. Lachkar S, Bota S, Nouvet G, Thiberville L: [Acute encephalopathy after infusion of paclitaxel]. Rev Mal Respir; 2006 Feb;23(1 Pt 1):73-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Paclitaxel is an anti-neoplastic agent commonly used in the treatment of primary bronchial carcinoma and tumours of the breast and ovary.
  • CASE REPORT: We report a case of acute encephalopathy, occurring eight hours after infusion of Paclitaxel, in a patient treated for adenocarcinoma of the lung.
  • The diagnosis of encephalopathy secondary to Paclitaxel injection was reached after exclusion of other possible aetiologies.

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16604029.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  • [Number-of-references] 12
  •  go-up   go-down


85. Oláh KS: Malignancy following treatment of borderline ovarian tumours: latent presentation of a Sister Joseph nodule following treatment of metastatic ovarian adenocarcinoma of the axilla. J Obstet Gynaecol; 2005 Feb;25(2):219-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignancy following treatment of borderline ovarian tumours: latent presentation of a Sister Joseph nodule following treatment of metastatic ovarian adenocarcinoma of the axilla.
  • [MeSH-major] Adenocarcinoma, Papillary / diagnosis. Neoplasm Recurrence, Local / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Axilla. Diagnosis, Differential. Edema / etiology. Female. Humans. Neoplasm Metastasis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15814420.001).
  • [ISSN] 0144-3615
  • [Journal-full-title] Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
  • [ISO-abbreviation] J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


86. Meinhold-Heerlein I, Bauerschlag D, Zhou Y, Sapinoso LM, Ching K, Frierson H Jr, Bräutigam K, Sehouli J, Stickeler E, Könsgen D, Hilpert F, von Kaisenberg CS, Pfisterer J, Bauknecht T, Jonat W, Arnold N, Hampton GM: An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma. Clin Cancer Res; 2007 Jan 15;13(2 Pt 1):458-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma.
  • PURPOSE: Cancer of the ovary confers the worst prognosis among women with gynecologic malignancies, underscoring the need to develop new biomarkers for detection of early disease, particularly those that can be readily monitored in the blood.
  • EXPERIMENTAL DESIGN: We developed an algorithm to identify secreted proteins encoded among approximately 22,500 genes on commercial oligonucleotide arrays and applied it to gene expression profiles of 67 stage I to IV serous papillary carcinomas and 9 crudely enriched normal ovarian tissues, to identify putative diagnostic markers.
  • RESULTS: We identified 275 genes predicted to encode secreted proteins with increased/decreased expression in ovarian cancers (<0.5- or >2-fold, P < 0.001).
  • The serum levels of four of these proteins (matrix metalloproteinase-7, osteopontin, secretory leukoprotease inhibitor, and kallikrein 10) were significantly elevated in a series of 67 independent patients with serous ovarian carcinomas compared with 67 healthy controls (P < 0.001, Wilcoxon rank sum test).
  • CONCLUSIONS: Our data suggest that this assay combination warrants further investigation as a multi-analyte diagnostic test for serous ovarian adenocarcinoma.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / genetics. Gene Expression Regulation, Neoplastic. Genomics / methods. Ovarian Neoplasms / blood. Ovarian Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17255266.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


87. Mijinyawa MS, Sani MU, Yusuf SM, Mohammed AZ, Alhassan SU: Krukenberg's tumour. Niger J Med; 2009 Oct-Dec;18(4):416-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Krukenburg's tumour, a metastatic cancer to the ovary can pose difficulties in early diagnosis.
  • METHODS: We present a 32-year-old lady who presented with mucoid and bloody diarrhoea associated with menstrual irregularity, weight loss and lower abdominal pains 2 years after surgical treatment for gastric cancer.
  • The histology of the colonic lesion showed signet ring carcinoma while the enlarged ovaries turned out to have evidence of metastatic adenocarcinoma.
  • CONCLUSION: Early diagnosis of KT can be difficult.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Signet Ring Cell / secondary. Colonic Neoplasms / secondary. Ovarian Neoplasms / secondary. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Fatal Outcome. Female. Humans

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20120149.001).
  • [ISSN] 1115-2613
  • [Journal-full-title] Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria
  • [ISO-abbreviation] Niger J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


88. Brun JL, Randriambelomanana J, Cherier L, Lafon ME, Trufflandier N, Le Bail B: Lymphoepithelioma-like carcinoma of the ovary: a case report and review of the literature. Int J Gynecol Pathol; 2010 Sep;29(5):427-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoepithelioma-like carcinoma of the ovary: a case report and review of the literature.
  • We present a case of an 82-year-old woman with a 10 cm LELC of the ovary shown by inguinal lymph nodes.
  • Cytoreductive surgery was performed to remove a left ovarian neoplasm and multiple involved lymph nodes.
  • The tumor was a mixed poorly undifferentiated ovarian carcinoma consisting of 95% LELC and 5% moderately differentiated serous adenocarcinoma.
  • To our knowledge, this is the second case of ovarian LELC and the first description of the native tumor before chemotherapy.
  • In conclusion, this rare tumor of the ovary is difficult to diagnose both preoperatively and perioperatively.
  • However, clinicians and pathologists should be aware that ovarian tumors with massive involvement of lymph nodes and no peritoneal carcinomatosis are suggestive of such a diagnosis and that prognosis is relatively good.
  • [MeSH-major] Carcinoma / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20736767.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


89. Kumbalek SL, Hanley CS, Matheson JS, Schutten MM, Gonzalez OD: What is your diagnosis? Ovarian adenocarcinoma. J Am Vet Med Assoc; 2006 Nov 15;229(10):1567-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What is your diagnosis? Ovarian adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / veterinary. Bird Diseases / diagnosis. Melopsittacus. Ovarian Neoplasms / veterinary
  • [MeSH-minor] Animals. Diagnosis, Differential. Fatal Outcome. Female. Kidney / pathology. Neoplasm Metastasis. Oviducts / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Am Vet Med Assoc. 2007 Feb 1;230(3):338-9; author reply 339 [17326288.001]
  • (PMID = 17107309.001).
  • [ISSN] 0003-1488
  • [Journal-full-title] Journal of the American Veterinary Medical Association
  • [ISO-abbreviation] J. Am. Vet. Med. Assoc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Venizelos ID, Tatsiou ZA, Roussos D, Karagiannis V: A case of sebaceous carcinoma arising within a benign ovarian cystic teratoma. Onkologie; 2009 Jun;32(6):353-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of sebaceous carcinoma arising within a benign ovarian cystic teratoma.
  • BACKGROUND: Mature cystic teratoma, also known as dermoid cyst, is the most common germ cell tumor of the ovary.
  • Malignant change in a component of a mature ovarian teratoma is rare, occurring in less than 2% of cases, with squamous cell carcinoma corresponding to 80% of such neoplasms.
  • Abdominal and pelvic ultrasound as well as computed tomography demonstrated a heterogenic tumor of the right ovary.
  • CONCLUSIONS: This is an extremely rare ovarian malignancy of which the clinical behavior and optimal management are not well established.
  • Differential diagnosis with other malignant neoplasms arising in mature cystic teratomas is exceedingly important for treatment and prognosis.
  • [MeSH-major] Adenocarcinoma, Sebaceous / diagnosis. Neoplasms, Multiple Primary / diagnosis. Ovarian Cysts / diagnosis. Ovarian Neoplasms / diagnosis. Teratoma / diagnosis

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cysts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19521124.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


91. Kawano K, Ushijima K, Fujimoto T, Komai K, Kamura T: Peptide YY producing strumal carcinoid of the ovary as the cause of severe constipation with contralateral epithelial ovarian cancer. J Obstet Gynaecol Res; 2007 Jun;33(3):392-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peptide YY producing strumal carcinoid of the ovary as the cause of severe constipation with contralateral epithelial ovarian cancer.
  • Primary ovarian carcinoid tumors are rare.
  • It has been reported that constipation was a presenting symptom in some patients with ovarian carcinoid.
  • A case of strumal carcinoid of the ovary with contralateral clear cell adenocarcinoma of the ovary discovered with a complaint of constipation is described.
  • Interestingly, the constipation caused by PYY also helped in discovering epithelial ovarian cancer.
  • [MeSH-major] Adenocarcinoma, Clear Cell / complications. Carcinoid Tumor / metabolism. Constipation / etiology. Ovarian Neoplasms / metabolism. Peptide YY / metabolism
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasms, Multiple Primary / complications. Neoplasms, Multiple Primary / metabolism. Neoplasms, Multiple Primary / pathology. Ovary / pathology


92. Aickin M, Taetle RM: Linksets of tumor chromosome breakpoints related to survival in ovarian adenocarcinoma. Cancer Genet Cytogenet; 2006 Apr 1;166(1):22-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Linksets of tumor chromosome breakpoints related to survival in ovarian adenocarcinoma.
  • Here, linkset models are fitted to data on chromosome breakpoints in ovarian adenocarcinomas, in order to answer the question motivating the project that collected them--whether there are nonrandom co-occurrences of breakpoints in particular chromosome regions, and whether these might be of prognostic significance.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Breakage. Genetic Linkage. Ovarian Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16616108.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA94750
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


93. Shukla P, Gupta D, Bisht SS, Pant MC: Ovarian adenocarcinoma in a young female with skin and umbilical metastasis. Indian J Med Paediatr Oncol; 2009 Oct;30(4):144-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian adenocarcinoma in a young female with skin and umbilical metastasis.
  • We report the case of ovarian carcinoma with skin and umbilical metastasis in a 30-year-old female.
  • The computed tomography (CT) scan of the abdomen showed a right ovarian mass with anterior abdominal wall metastasis.
  • The CT-guided fine needle aspiration cytology (FNAC) from the ovarian mass showed adenocarcinoma.
  • FNAC from the umbilical and skin metastasis also showed adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20838558.001).
  • [ISSN] 0975-2129
  • [Journal-full-title] Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
  • [ISO-abbreviation] Indian J Med Paediatr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2930304
  • [Keywords] NOTNLM ; Ovarian carcinoma / skin metastasis / umbilical metastasis
  •  go-up   go-down


94. Shidham VB, Komorowski RA, Machhi JK: Androgen receptor expression in metastatic adenocarcinoma in females favors a breast primary. Diagn Pathol; 2006;1:34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Androgen receptor expression in metastatic adenocarcinoma in females favors a breast primary.
  • BACKGROUND: The differential diagnosis of metastatic mammary adenocarcinoma and adenocarcinomas from other primary sites can be challenging, particularly in tumors that are poorly differentiated and negative for Estrogen/Progesterone receptors (ER/PR).
  • This study was undertaken to evaluate the diagnostic significance of AR expression in adenocarcinoma of breast and other morphologically similar adenocarcinomas.
  • DESIGN: Formalin-fixed paraffin-embedded tissue sections of 113 primary adenocarcinoma of various sites [breast (34, all females), lung (23, M- 6, F-17), colon (9, M-2, F-7), stomach (6, M-4, F-2), liver and bile duct (11, M-5, F-6), pancreas (7, M-2, F-5), ovary (10), endometrium (7), and cervix (6)] were immunostained with monoclonal antibody for AR.
  • RESULTS: 56% (19/34) mammary carcinoma and 20% (2/10) adenocarcinoma of ovary were positive for AR.
  • CONCLUSION: Significant proportion of mammary carcinomas and some ovarian carcinomas express AR in the nuclei of more than 10% tumor cells.
  • If metastatic tumor with unknown primary in a female is AR positive, breast and ovary are the most likely primary sites.
  • Cytoplasmic immunoreactivity alone without nuclear immunoreactivity for AR was non-specific for this differential diagnosis.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 1995 Jan-Feb;45(1):8-30 [7528632.001]
  • [Cites] Hum Pathol. 1998 Dec;29(12):1428-32 [9865828.001]
  • [Cites] J Am Acad Dermatol. 1995 May;32(5 Pt 1):711-6 [7722013.001]
  • [Cites] Mod Pathol. 2000 Feb;13(2):119-22 [10697267.001]
  • [Cites] Am J Surg Pathol. 2000 Apr;24(4):579-86 [10757407.001]
  • [Cites] Am J Clin Pathol. 2002 May;117(5):745-50 [12090423.001]
  • [Cites] Acta Cytol. 2002 Jul-Aug;46(4):651-8 [12146025.001]
  • [Cites] Am J Clin Pathol. 2003 Jun;119(6):801-6 [12817426.001]
  • [Cites] J Urol. 1992 Mar;147(3 Pt 2):798-803 [1371552.001]
  • [Cites] Int J Cancer. 1992 Oct 21;52(4):581-4 [1399140.001]
  • [Cites] Am J Clin Pathol. 2003 Nov;120(5):725-31 [14608899.001]
  • [Cites] Int Rev Cytol. 1975;41:87-172 [166046.001]
  • [Cites] J Histochem Cytochem. 1991 Jul;39(7):927-36 [1865110.001]
  • [Cites] Cancer Res. 1989 Dec 15;49(24 Pt 1):7162-7 [2582456.001]
  • [Cites] J Steroid Biochem. 1987 Mar;26(3):393-7 [3495702.001]
  • [Cites] Eur J Cancer Clin Oncol. 1985 Apr;21(4):539-42 [4007019.001]
  • [Cites] J Pathol. 1993 May;170(1):31-5 [8100853.001]
  • [Cites] J Histochem Cytochem. 1994 Jun;42(6):783-8 [8189040.001]
  • [Cites] Hum Pathol. 1993 Jan;24(1):90-5 [8418017.001]
  • [Cites] Cancer. 1996 Mar 1;77(5):934-40 [8608487.001]
  • [Cites] Mod Pathol. 1995 Dec;8(9):897-901 [8751328.001]
  • [Cites] Br J Cancer. 1996 Oct;74(8):1175-80 [8883401.001]
  • [Cites] Histopathology. 1996 Sep;29(3):233-40 [8884351.001]
  • [Cites] Anticancer Res. 1996 Nov-Dec;16(6B):3803-6 [9042261.001]
  • [Cites] Mod Pathol. 1997 Aug;10(8):839-45 [9267828.001]
  • [Cites] Mod Pathol. 1998 Nov;11(11):1033-8 [9831198.001]
  • [Cites] Mod Pathol. 1998 Nov;11(11):1122-6 [9831211.001]
  • [Cites] Ann Surg Oncol. 1994 Nov;1(6):495-503 [7531602.001]
  • (PMID = 17020615.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1601970
  •  go-up   go-down


95. Heinritz W, Strenge S, Kujat A, Hockel M, Froster UG: Different phenotypes including gynecological cancer in three female patients with Peutz-Jeghers syndrome and mutations in the STK11 gene. Onkologie; 2008 Nov;31(11):625-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different phenotypes including gynecological cancer in three female patients with Peutz-Jeghers syndrome and mutations in the STK11 gene.
  • Patients are at an increased cancer risk not only for gastrointestinal but also for extraintestinal neoplasms.
  • PATIENTS AND RESULTS: We report on the clinical and molecular findings in 3 young female patients with PJS; 2 of them suffered from severe gynecological cancer.
  • One patient died at the age of 29 years of an incurable mucin-producing cervical adenocarcinoma.
  • Another patient had a papillary serous carcinoma of the ovary.
  • CONCLUSION: PJS should be considered in differential diagnosis in young women with gynecological malignancies.
  • [MeSH-major] Biomarkers, Tumor / genetics. Genital Neoplasms, Female / diagnosis. Genital Neoplasms, Female / genetics. Peutz-Jeghers Syndrome / diagnosis. Peutz-Jeghers Syndrome / genetics. Polymorphism, Single Nucleotide / genetics. Protein-Serine-Threonine Kinases / genetics

  • Genetic Alliance. consumer health - Peutz Jeghers syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19145097.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; EC 2.7.1.- / STK11 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


96. Lin X, Lindner JL, Silverman JF, Liu Y: Intestinal type and endocervical-like ovarian mucinous neoplasms are immunophenotypically distinct entities. Appl Immunohistochem Mol Morphol; 2008 Oct;16(5):453-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal type and endocervical-like ovarian mucinous neoplasms are immunophenotypically distinct entities.
  • Ovarian mucinous neoplasm (OMN) is traditionally classified as either intestinal type or endocervical-like subtypes.
  • In this study, we investigated 14 intestinal type OMNs (borderline and adenocarcinoma) and 12 endocervical-like OMNs (borderline and adenocarcinoma) for their expression of PDX-1, CDX-2, CA-125, CK7, CK20, WT-1, D2-40, and TTF-1.
  • We also included 15 colorectal adenocarcinomas metastatic in the ovary, as they may occasionally mimic OMN.
  • The 2 subtypes can be separated from metastatic colorectal adenocarcinoma by the different immunohistochemical profile of PDX-1, CA-125, CK7, CK20, and CDX-2.
  • In the work-up of mucinous adenocarcinoma in the ovary or abdominal cavity, caution should be exercised in interpreting the possible primary site on the basis of the immunohistochemical profiles.


97. Giles JR, Olson LM, Johnson PA: Characterization of ovarian surface epithelial cells from the hen: a unique model for ovarian cancer. Exp Biol Med (Maywood); 2006 Dec;231(11):1718-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of ovarian surface epithelial cells from the hen: a unique model for ovarian cancer.
  • To further develop the hen as a model of ovarian adenocarcinoma, we have studied normal and neoplastic ovaries as well as cultured cells from the ovarian surface epithelium (OSE).
  • We also isolated and characterized the epithelial cells that are the likely source of the ovarian tumors of the hen.
  • The surface epithelium of normal ovaries demonstrated positive staining for cytokeratin, proliferating cell nuclear antigen (PCNA), progesterone receptor (PR), and negative staining for vimentin.
  • Ovarian tumors demonstrated positive cytokeratin, PCNA, PR, and weak vimentin staining in the gland-like areas.
  • [MeSH-major] Epithelial Cells / cytology. Epithelial Cells / pathology. Ovarian Neoplasms / pathology. Ovary / cytology. Ovary / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / physiopathology. Animals. Biomarkers. Chickens. Disease Models, Animal. Female. Keratins / analysis. Proliferating Cell Nuclear Antigen / analysis. Receptors, Progesterone / analysis. Reference Values. Vimentin / analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17138758.001).
  • [ISSN] 1535-3702
  • [Journal-full-title] Experimental biology and medicine (Maywood, N.J.)
  • [ISO-abbreviation] Exp. Biol. Med. (Maywood)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Proliferating Cell Nuclear Antigen; 0 / Receptors, Progesterone; 0 / Vimentin; 68238-35-7 / Keratins
  •  go-up   go-down


98. Malhotra N, Sumana G, Singh A, Deka D, Mittal S: Rupture of a malignant ovarian tumor in pregnancy presenting as acute abdomen. Arch Gynecol Obstet; 2010 May;281(5):959-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rupture of a malignant ovarian tumor in pregnancy presenting as acute abdomen.
  • INTRODUCTION: Ovarian neoplasms in pregnancy are usually asymptomatic rarely leading onto complications.
  • A 30-year-old G2 P1+0+0+1 was referred at 30 weeks of pregnancy with an ultrasound diagnosis of a large multicystic ovarian cyst with no solid areas, ascites or evidence of metastasis.
  • Clinical examination revealed a relaxed uterus and ultrasound was suggestive of rupture of the ovarian cyst.
  • Exploratory laparotomy revealed a ruptured left mucinous ovarian cyst with no evidence of solid areas or metastasis.
  • Histopathology revealed stage-1c mucinous cyst adenocarcinoma of left ovary.
  • CONCLUSION: This is the first reported case of a ruptured malignant ovarian tumor in pregnancy.
  • Torsion or rupture of ovarian masses is an important differential diagnosis of abdominal or pelvic pain during pregnancy.
  • [MeSH-major] Abdomen, Acute / etiology. Adenocarcinoma, Mucinous / complications. Ovarian Neoplasms / complications. Ovary / pathology. Pregnancy Complications, Neoplastic / pathology

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19949808.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


99. Horváth V, Blanárová O, Svihálková-Sindlerová L, Soucek K, Hofmanová J, Sova P, Kroutil A, Fedorocko P, Kozubík A: Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells. Gynecol Oncol; 2006 Jul;102(1):32-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells.
  • OBJECTIVES: The resistance of tumor cells to cisplatin remains a major cause of treatment failure in cancer patients.
  • METHODS: The ovarian adenocarcinoma SK-OV-3 cells were exposed to cisplatin, LA-9, or LA-12 for 72 h and the effects of drug concentrations that caused 10% or 50% inhibition of cell proliferation were determined.
  • RESULTS: Lung Resistance-related Protein (LRP/MVP) was detected in SK-OV-3 cells but not in the other two ovarian cancer lines with different sensitivity to cisplatin.
  • Interestingly, Pt(IV) complex-LA-12 had approximately 2.7-fold lower IC(50) concentration than LA-9 or cisplatin in SK-OV-3 cells.
  • Overall, LA-12 but not its reduced Pt(II) counterpart LA-9 is the compound effective in p53 null human ovarian cancer cells and it is able to overcome intrinsic cisplatin resistance in these cells.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Organoplatinum Compounds / pharmacology. Ovarian Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. AMANTADINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16364413.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; 0 / Organoplatinum Compounds; 0 / Vault Ribonucleoprotein Particles; 0 / bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV); 0 / major vault protein; BF4C9Z1J53 / Amantadine; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


100. Yang R, Feng J, Fang XZ, Bai F, Cheng YX, Liu C, Zhu W, Li L: [Construction and utilization of the prognostic model of serous ovarian adenocarcinoma]. Zhonghua Fu Chan Ke Za Zhi; 2006 Jul;41(7):459-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Construction and utilization of the prognostic model of serous ovarian adenocarcinoma].
  • OBJECTIVE: To analyze the related factors with prognosis in patients with serous ovarian adenocarcinoma and to set up a prognostic model of serous ovarian adenocarcinoma.
  • METHODS: The clinical, pathological and follow-up data of 104 cases with serous ovarian adenocarcinoma were retrospectively analyzed.
  • And the prognostic model of serous ovarian adenocarcinoma was set up based on the result of the above study, which could be used to deduce the survival probability of patients with serous ovarian adenocarcinoma.
  • RESULTS: International Federation of Gynecology and Obstetrics (FIGO) stage (P = 0.0029), histological grade (P = 0.0054), residual disease (P = 0.0000), metastasis of lymph nodes (P = 0.0000) and chemotherapy (P = 0.0000) were the related factors of prognosis in patients with serous ovarian adenocarcinoma, of which FIGO stage was the most important one, followed sequentially by histological grade, metastasis of lymph node, residual disease and chemotherapy (the independent risk coefficient of each factor was 1.3392, 0.9206, 0.7071, 0.6004, 0.4985 in sequence).
  • CONCLUSIONS: FIGO stage, histological grade, residual disease, metastasis of lymph nodes and chemotherapy are important prognostic factors of serous ovarian adenocarcinoma.
  • This model can be used to estimate the prognosis of patients with serous ovarian adenocarcinoma, and the effect of both chemotherapy and residual disease on the prognosis could be quantified by the model.
  • [MeSH-major] Cystadenocarcinoma, Serous / pathology. Models, Statistical. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17083811.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down






Advertisement